avibactam profile

avibactam : A member of the class of azabicycloalkanes that is (2S,5R)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide in which the amino hydrogen at position 6 is replaced by a sulfooxy group. Used (in the form of its sodium salt) in combination with ceftazidime pentahydrate for the treatment of complicated urinary tract infections including pyelonephritis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	9835049
CHEMBL ID	1689063
CHEBI ID	85984
SCHEMBL ID	1666807
MeSH ID	M0576517

Synonym
avibactam (free acid)
HY-14879
CHEMBL1689063 ,
nxl-104 free acid
nxl104
avibactam
chebi:85984 ,
bdbm50339145
trans-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octan-2-carboxamide
unii-7352665165
1192500-31-4
avibactam [usan:inn]
CS-0593
avibactam [usan]
sulfuric acid, mono((1r,2s,5r)-2-(aminocarbonyl)-7-oxo-1,6-diazabicyclo(3.2.1)oct-6-yl) ester
(1r,2s,5r)-7-oxo-6-sulfooxy-1,6-diazabicyclo(3.2.1)octane-2-carboxamide
avibactam [inn]
zavicefta component avibactam
avibactam [who-dd]
avibactam component of zavicefta
avibactam [mi]
avibactam, (+/-)-
794508-22-8
06mfo7817i ,
unii-06mfo7817i
1,6-diazabicyclo(3.2.1)octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, (1r,2s,5r)-rel-
ave-1330a free acid
396731-14-9
SCHEMBL1666807
(2s,5r)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
DB09060
AKOS030526076
avibactam free acid
sulfuric acid, mono[(1r,2s,5r)-2-(aminocarbonyl)-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl] ester
(1r,2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulfate
Q15410251
AMY24028
[(2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate
gtpl10761
MS-23747
AC-35749
E80372
DTXSID901026066
[(2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl]oxidanesulfonic acid
1416134-69-4
EN300-22179568
avibactamfreeacid

Excerpt	Reference	Relevance
"Avibactam is a non β-lactam β-lactamase inhibitor that has recently been approved in association with a β-lactam antibiotic for the treatment of severe infections caused by otherwise resistant bacteria. "	( Synthetic approaches towards avibactam and other diazabicyclooctane β-lactamase inhibitors. Cariou, K; Peilleron, L, 2020)	2.29
"Avibactam is a β-lactamase inhibitor that is combined with aztreonam against Enterobacterales co-expressing serine- and metallo-β-lactamases (MBL). "	( Pragmatic options for dose optimization of ceftazidime/avibactam with aztreonam in complex patients. Baldelli, S; Cattaneo, D; Di Paolo, A; Falcone, M; Galfo, V; Leonildi, A; Menichetti, F; Pai, MP; Tagliaferri, E; Tiseo, G, 2021)	2.31
"Avibactam is a potent diazobicyclooctane inhibitor of class A and C β-lactamases. "	( Inhibition of the Lee, M; Smith, CA; Stasyuk, A; Stewart, NK; Toth, M; Vakulenko, SB, 2021)	2.06
"Avibactam is a novel broad-range β-lactamase inhibitor active against Ambler class A (including ESBL and KPC) and some Ambler class C and D (e.g. "	( Emergence of ceftazidime/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate. Aepfelbacher, M; Belmar Campos, C; Both, A; Büttner, H; Christner, M; Huang, J; Kluge, S; König, C; Maurer, FP; Perbandt, M; Rohde, H; Wichmann, D, 2017)	2.2
"Avibactam is a non-β-lactam β-lactamase inhibitor for treating complicated urinary tract and respiratory infections caused by multidrug-resistant bacterial pathogens, a serious public health threat. "	( Molecular Insights on the Release of Avibactam from the Acyl-Enzyme Complex. Delgado, EJ; Lizana, I, 2019)	2.23
"Avibactam is a novel, covalent, non-β-lactam β-lactamase inhibitor presently in clinical development in combination with either ceftaroline or ceftazidime."	( Structural insight into potent broad-spectrum inhibition with reversible recyclization mechanism: avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC β-lactamases. Benvenuti, M; De Luca, F; Docquier, JD; Durand-Reville, T; Lahiri, SD; Mangani, S; Sanyal, G, 2013)	1.33
"Avibactam is a non-β-lactam β-lactamase inhibitor with a spectrum of activity that includes β-lactamase enzymes of classes A, C, and selected D examples. "	( Kinetics of avibactam inhibition against Class A, C, and D β-lactamases. Durand-Réville, TF; Ehmann, DE; Fisher, SL; Gao, N; Gu, RF; Hu, J; Jahic, H; Lahiri, S; Livchak, S; Palmer, T; Ross, PL; Thresher, J; Walkup, GK, 2013)	2.21
"Avibactam is a novel non-β-lactam β-lactamase inhibitor that inhibits Ambler class A, C, and some D enzymes."	( Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012. Castanheira, M; Farrell, DJ; Flamm, RK; Jones, RN; Sader, HS, 2014)	1.39
"Avibactam is a novel non-β-lactam β-lactamase inhibitor that is currently undergoing phase 3 clinical trials in combination with ceftazidime. "	( Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model. Borgonovi, M; Coleman, K; Drusano, G; Girard, AM; Levasseur, P; Merdjan, H; Miossec, C; Nichols, WW; Shlaes, D, 2014)	2.13
"Avibactam is a bridged diazabicyclo [3.2.1]octanone non-β-lactam β-lactamase inhibitor in clinical development that reversibly inactivates serine β-lactamases."	( Reclaiming the efficacy of β-lactam-β-lactamase inhibitor combinations: avibactam restores the susceptibility of CMY-2-producing Escherichia coli to ceftazidime. Bonomo, RA; Chilakala, S; Gatta, JA; Johnson, JK; Papp-Wallace, KM; Taracila, MA; Winkler, ML; Xu, Y, 2014)	1.36
"Avibactam is a non-β-lactam inhibitor of Ambler class A, class C and some class D β-lactamases that is in clinical development with several β-lactam agents."	( Activity of avibactam against Enterobacter cloacae producing an extended-spectrum class C β-lactamase enzyme. Alm, RA; Giacobbe, RA; Johnstone, MR; Lahiri, SD, 2014)	1.5
"Avibactam is a novel non-β-lactam β-lactamase inhibitor that inhibits a wide range of β-lactamases. "	( Avibactam and class C β-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance. Alm, RA; Johnstone, MR; Lahiri, SD; McLaughlin, RE; Olivier, NB; Ross, PL, 2014)	3.29
"Avibactam is a novel β-lactamase inhibitor that restores the activity of otherwise hydrolyzed β-lactams against Gram-negative bacteria expressing different classes of serine β-lactamases. "	( Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases. Abdelhamed, AM; Bajaksouzian, S; Bonomo, RA; Foster, AN; Gatta, JA; Jacobs, MR; Nichols, WW; Papp-Wallace, KM; Testa, R; Winkler, ML, 2015)	2.09
"Avibactam is a novel non-β-lactam β-lactamase inhibitor currently being assessed in combination with ceftazidime, ceftaroline fosamil, and aztreonam. "	( Effect of age and sex on the pharmacokinetics and safety of avibactam in healthy volunteers. Merdjan, H; Tarral, A, 2015)	2.1
"Avibactam is a novel non-β-lactam β-lactamase inhibitor effective against Ambler class A, C and some class D β-lactamases that is currently in clinical development in combination with ceftazidime for the treatment of serious Gram-negative infections. "	( Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies. Merdjan, H; Rangaraju, M; Tarral, A, 2015)	2.09
"Avibactam is a novel non-β-lactam β-lactamase inhibitor that has been shown to restore the in vitro activity of ceftazidime against pathogens producing Ambler class A, C, and some class D β-lactamases. "	( Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime-avibactam in healthy Japanese volunteers. Bouw, MR; Das, S; Edeki, T; Learoyd, M; Li, J; Tominaga, N, 2015)	2.09
"Avibactam is a new non-β-lactam β-lactamase inhibitor that shows promising restoration of ceftazidime activity against microorganisms producing Ambler class A extended-spectrum β-lactamases (ESBLs) and carbapenemases such as KPCs, class C β-lactamases (AmpC), and some class D enzymes. "	( Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection. Berkhout, J; Lagarde, CM; Melchers, MJ; Mouton, JW; Nichols, WW; Schuck, VJ; Seyedmousavi, S; van Mil, AC, 2016)	2.15
"Avibactam is a novel non-β-lactam β-lactamase inhibitor that covalently acylates a variety of β-lactamases, causing inhibition. "	( Distinctive Binding of Avibactam to Penicillin-Binding Proteins of Gram-Negative and Gram-Positive Bacteria. Asli, A; Brouillette, E; Krause, KM; Malouin, F; Nichols, WW, 2016)	2.19
"Avibactam is a novel non-β-lactam β-lactamase inhibitor that, in combination with ceftazidime, has recently obtained regulatory approval in the USA."	( Structural and sequence analysis of class A β-lactamases with respect to avibactam inhibition: impact of Ω-loop variations. Alm, RA; Bradford, PA; Lahiri, SD; Nichols, WW, 2016)	1.39
"Avibactam is a non-β-lactam β-lactamase inhibitor intended for use as a fixed-dose combination with ceftazidime for the treatment of certain serious Gram-negative infections. "	( Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients With Renal Impairment. Das, S; Li, J; Merdjan, H; Tarral, A, 2017)	2.13
"Avibactam is a novel non-β-lactam β-lactamase inhibitor being developed in combination with ceftazidime, ceftaroline and aztreonam for the treatment of infections caused by Gram-negative bacteria. "	( Impact of defined cell envelope mutations in Escherichia coli on the in vitro antibacterial activity of avibactam/β-lactam combinations. Huband, MD; McLeod, SM; Nichols, WW; Patey, SA, 2017)	2.11
"Avibactam is a β-lactamase inhibitor that is in clinical development, combined with β-lactam partners, for the treatment of bacterial infections comprising gram-negative organisms. "	( Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. Ehmann, DE; Fisher, SL; Gu, RF; Hu, J; Jahić, H; Kern, G; Ross, PL; Walkup, GK, 2012)	3.26

Excerpt	Reference	Relevance
"Avibactam has an unusual mechanism of action: it is a covalent inhibitor that acts via ring opening, but in contrast to other currently used β-lactamase inhibitors, this reaction is reversible."	( Avibactam and class C β-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance. Alm, RA; Johnstone, MR; Lahiri, SD; McLaughlin, RE; Olivier, NB; Ross, PL, 2014)	2.57
"Avibactam has a spectrum of inhibition of class A and C β-lactamases, including ESBLs, AmpC and Klebsiella pneumoniae carbapenemase (KPC) enzymes."	( Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections. Falcone, M; Paterson, D, 2016)	1.46

Excerpt	Reference	Relevance
"Avibactam displays potent inhibition of extended-spectrum, AmpC, KPC and some OXA β-lactamases. "	( In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations. Aoki, K; Ishii, Y; Nichols, WW; Tateda, K; Testa, R; Yoshizumi, A, 2015)	2.06
"Avibactam does not inhibit MBLs and binds only weakly to most of the MBLs tested; in some cases, avibactam undergoes slow hydrolysis of one of its urea N-CO bonds followed by loss of CO2, in a process different from that observed with the SBLs studied."	( Interaction of Avibactam with Class B Metallo-β-Lactamases. Abboud, MI; Brem, J; Claridge, TD; Damblon, C; Frère, JM; Gilbert, B; Mercuri, P; Rydzik, AM; Schofield, CJ; Smargiasso, N, 2016)	1.51

Excerpt	Reference	Relevance
" Adverse events were observed in 67."	( Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Duttaroy, DD; González Patzán, LD; Kreidly, Z; Lipka, J; Sable, C; Stricklin, D; Vazquez, JA, 2012)	0.66
" Infusions of ceftaroline fosamil/avibactam were well tolerated at total daily doses of up to 1,800 mg of each compound, and all adverse events (AEs) were mild to moderate in severity."	( Single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjects. Rank, D; Riccobene, TA; Su, SF, 2013)	0.87
" The incidence of treatment-emergent adverse events was similar for ceftazidime/avibactam plus metronidazole (64."	( Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial. Lipka, J; Lucasti, C; Popescu, I; Ramesh, MK; Sable, C, 2013)	0.86
" The most common adverse event was administration/venipuncture site bruising (6 events); all adverse events were mild."	( Effect of age and sex on the pharmacokinetics and safety of avibactam in healthy volunteers. Merdjan, H; Tarral, A, 2015)	0.66
"No serious or severe adverse events were reported in either study."	( Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies. Merdjan, H; Rangaraju, M; Tarral, A, 2015)	0.65
" There were no deaths or serious adverse events."	( Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime-avibactam in healthy Japanese volunteers. Bouw, MR; Das, S; Edeki, T; Learoyd, M; Li, J; Tominaga, N, 2015)	0.65
" Adverse events (AEs) were similar between cohorts."	( Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study. Arenz, D; Calbo, E; Cisneros, JM; Cornely, OA; Horcajada, JP; Jiménez-Jorge, S; Luckey, A; O'Brien, S; Queckenberg, C; Raber, S; Rodríguez-Hernández, MJ; Rosso-Fernández, CM; Tallón-Aguilar, L; Torre-Cisneros, J; Turner, G; Zettelmeyer, U, 2020)	0.82
"Many antibiotics are well known for being associated with adverse events (AEs) of central nervous system, ceftazidime/avibactam (CAZ/AVI) is a novel β-lactam/β-lactamase inhibitor combinations."	( Central nervous system adverse events of ceftazidime/avibactam: A retrospective study using Food and Drug Administration Adverse Event Reporting System. Cui, X; Guo, M; Guo, X; Li, J, 2022)	1.18

Excerpt	Reference	Relevance
" Dose fractionation experiments identified that "time > threshold" was the pharmacodynamic index linked to cell kill and resistance suppression."	( Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases. Brown, D; Castanheira, M; Critchley, I; Drusano, GL; Grasso, C; Jones, RN; Kulawy, R; Liu, W; Louie, A; Thye, D; Vanscoy, B; Williams, G, 2012)	0.38
" No significant differences in systemic exposure of ceftaroline or avibactam were observed when the drugs were administered alone versus concomitantly, indicating that there was no apparent pharmacokinetic interaction between ceftaroline fosamil and avibactam administered as a single dose."	( Single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjects. Rank, D; Riccobene, TA; Su, SF, 2013)	0.83
" To determine possible clinical use, it is important to know the pharmacokinetic profiles of the compounds related to each other in plasma and the different compartments of infection in experimentally infected animals and in humans."	( Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice. Berkhout, J; Lagarde, CM; Melchers, MJ; Mouton, JW; Nichols, WW; Seyedmousavi, S; van Mil, AC, 2015)	0.67
" Pharmacokinetic measurements included Cmax, Tmax, AUC0-∞, plasma clearance, and t½."	( Effect of age and sex on the pharmacokinetics and safety of avibactam in healthy volunteers. Merdjan, H; Tarral, A, 2015)	0.66
" Mean Cmax was similar in young male, young female, and elderly female subjects (33."	( Effect of age and sex on the pharmacokinetics and safety of avibactam in healthy volunteers. Merdjan, H; Tarral, A, 2015)	0.66
" Concomitant ceftazidime did not affect avibactam's safety and pharmacokinetic profile."	( Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies. Merdjan, H; Rangaraju, M; Tarral, A, 2015)	0.92
" Pharmacokinetic (PK)/pharmacodynamic (PD) understanding of this combination is critical for optimal clinical dose selection."	( Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam. Bradford, PA; Eakin, AE; Harris, JJ; Kim, A; McLaughlin, RE; O'Donnell, JP; Patey, S; Singh, R; Tanudra, MA, 2015)	0.63
" To determine optimal dosing combinations of ceftazidime-avibactam for treating infections with ceftazidime-resistant Pseudomonas aeruginosa, pharmacodynamic responses were explored in murine neutropenic thigh and lung infection models."	( Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection. Berkhout, J; Lagarde, CM; Melchers, MJ; Mouton, JW; Nichols, WW; Schuck, VJ; Seyedmousavi, S; van Mil, AC, 2016)	0.95
"Using an in vitro pharmacokinetic model we simulated human drug concentration-time courses associated with ceftaroline 600 mg every 8 h and ceftazidime 2000 mg every 8 h."	( The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection. Bowker, K; MacGowan, A; Noel, A; Tomaselli, S, 2017)	0.76
"As AUC is a much easier and more reliable pharmacokinetic measure than C max , it would be useful to explore how AUC-based indices for avibactam exposures could be used for translating the results of the present study into patients' therapy."	( The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection. Bowker, K; MacGowan, A; Noel, A; Tomaselli, S, 2017)	0.97
"Our objective was to develop population pharmacokinetic (PK) models for ceftazidime and avibactam in the plasma and epithelial lining fluid (ELF) of healthy volunteers and to compare ELF concentrations to plasma PK/pharmacodynamic (PD) targets."	( Population Pharmacokinetic Modelling of Ceftazidime and Avibactam in the Plasma and Epithelial Lining Fluid of Healthy Volunteers. Das, S; Dimelow, R; MacPherson, M; Newell, P; Wright, JG, 2018)	0.95
" The focus of this review was to provide clinical pharmacokinetic data of avibactam to cover absorption, distribution, metabolism, and excretion aspects including any potential for avibactam to show drug-drug interactions in the clinic."	( Review of Clinical Pharmacokinetics of Avibactam, A Newly Approved non-β lactam β-lactamase Inhibitor Drug, In Combination Use With Ceftazidime. Giri, P; Patel, H; Srinivas, NR, 2019)	1.01
" aeruginosa to compare different pharmacodynamic indices derived from simulated human avibactam exposures, with respect to their degree of correlation with the modelled bacterial responses."	( A model-based analysis of pharmacokinetic-pharmacodynamic (PK/PD) indices of avibactam against Pseudomonas aeruginosa. Derendorf, H; Nichols, WW; Schuck, VJ; Sy, SKB; Xia, H; Zhuang, L, 2019)	0.97
"Checkerboard experiments followed by fractional inhibitory concentration (FIC) index determinations are commonly used to assess in vitro pharmacodynamic interactions between combined antibiotics, but FIC index cannot be determined in case of antibiotic/non-active compound combinations."	( Pharmacodynamic modelling of β-lactam/β-lactamase inhibitor checkerboard data: illustration with aztreonam-avibactam. Buyck, J; Chauzy, A; Couet, W; de Jonge, BLM; Grégoire, N; Marchand, S, 2019)	0.73
" The aim of this study was to evaluate whether the addition of avibactam could reduce or close the mutant selection window (MSW) of aztreonam in Escherichia coli and Klebsiella pneumoniae harbouring MBLs; MSW is a pharmacodynamic (PD) parameter for the selection of emergent resistant mutants."	( Aztreonam/avibactam effect on pharmacodynamic indices for mutant selection of Escherichia coli and Klebsiella pneumoniae harbouring serine- and New Delhi metallo-β-lactamases. Dong, D; Feng, K; Gong, H; Jia, N; Liu, Y; Lv, Z; Martins, FS; Sy, S; Sy, SKB; Yu, M; Zhang, J; Zhu, P; Zhu, S; Zhu, Y, 2021)	1.26
" Extensive population pharmacokinetic (PK) data sets for ceftazidime and avibactam obtained during the adult clinical development program were used to iteratively select, modify, and validate the approved adult dosage regimen (2,000-500 mg by 2-hour intravenous (IV) infusion every 8 hours (q8h), with adjustments for renal function)."	( Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime-Avibactam in Pediatric Patients Aged 3 Months and Older. Bradley, JS; Carrothers, TJ; Chan, PLS; Franzese, RC; Lovern, M; McFadyen, L; Raber, S; Riccobene, T; Vourvahis, M; Watson, KJ, 2022)	1.17
"The objective of this pharmacokinetic (PK)/pharmacodynamic (PD) analysis was to evaluate the efficacy of different dosing regimens of ceftazidime/avibactam (CZA) for the treatment of pulmonary infections by extensively drug-resistant (XDR) Pseudomonas aeruginosa using optimized two-step administration therapy (OTAT) and traditional infusion (TI)."	( Evaluation of the Efficacy of Optimized Two-Step-Administration Therapy with Ceftazidime/Avibactam for Treating Extensively Drug-Resistant Pseudomonas aeruginosa Pulmonary Infections: a Pharmacokinetic/Pharmacodynamic Analysis. Cui, J; Kang, Y, 2023)	1.33
"In this study, a systematic analysis of the pharmacodynamic interactions of ceftazidime/avibactam and fosfomycin in clinical and isogenic Escherichia coli strains carrying genes coding for several carbapenemases or ESBLs was performed and pharmacodynamic interactions were quantified by modelling and simulations."	( Evaluation of in vitro pharmacodynamic drug interactions of ceftazidime/avibactam and fosfomycin in Escherichia coli. Decousser, JW; Grégoire, N; Kroemer, N; Martens, M; Nordmann, P; Wicha, SG, 2023)	1.36

Excerpt	Reference	Relevance
"The in vitro activity of ceftazidime in combination with NXL104 versus 470 Pseudomonas aeruginosa clinical isolates was evaluated using Clinical and Laboratory Standards Institute (CLSI) broth microdilution methods."	( In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study). DeCorby, M; Hoban, DJ; Karlowsky, JA; Lagacé-Wiens, PR; Walkty, A; Zhanel, GG, 2011)	0.37
"Ceftaroline exhibits in vitro activity against extended-spectrum β-lactamase (ESBL)-, AmpC-, and KPC-producing Enterobacteriaceae when combined with the novel β-lactamase inhibitor NXL104."	( In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae. Crandon, JL; Furtado, GH; Nicolau, DP; Williams, G; Wiskirchen, DE, 2011)	0.37
" In this evaluation, we examined organisms carrying defined β-lactamases and identified doses and schedules of NXL104 in combination with the new cephalosporin ceftaroline, which would maintain good bacterial cell kill and suppress resistance emergence for a clinically relevant period of 10 days in our hollow-fiber infection model."	( Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases. Brown, D; Castanheira, M; Critchley, I; Drusano, GL; Grasso, C; Jones, RN; Kulawy, R; Liu, W; Louie, A; Thye, D; Vanscoy, B; Williams, G, 2012)	0.38
"The objective of this study was to investigate the in vitro antibacterial activity of avibactam (formerly NXL104) in combination with imipenem, cefepime or ceftazidime against Gram-negative bacteria."	( In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae. Aktaş, Z; Kayacan, C; Oncul, O, 2012)	0.92
" In this study, the activity of NXL104 in combination with the third-generation cephalosporins ceftazidime (CAZ) and ceftriaxone (CRO) or with piperacillin (PIP) was evaluated against 316 anaerobic bacteria."	( Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole. Dubreuil, LJ; Mahieux, S; Miossec, C; Neut, C; Pace, J, 2012)	0.38
"This study was conducted to determine the safety, tolerability, and pharmacokinetics of intravenous doses of ceftaroline fosamil administered in combination with the novel non-β-lactam β-lactamase inhibitor avibactam in healthy adults."	( Single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjects. Rank, D; Riccobene, TA; Su, SF, 2013)	0.78
"Avibactam, a novel non-β-lactam β-lactamase inhibitor with activity against Ambler class A, class C, and some class D enzymes is being evaluated in combination with various β-lactam antibiotics to treat serious bacterial infections."	( Assessment of the mass balance recovery and metabolite profile of avibactam in humans and in vitro drug-drug interaction potential. Atherton, J; Clarkson-Jones, J; Das, S; Edeki, T; Gupta, A; Mair, S; Vishwanathan, K, 2014)	2.08
" MIC(90) values (minimum inhibitory concentration that inhibits 90% of the isolates) of ceftazidime, ceftaroline and aztreonam for Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Enterobacter aerogenes, Citrobacter freundii and Morganella morganii were reduced up to 128-fold or greater when combined with avibactam."	( In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates. Cantón, R; Giani, T; Morosini, MI; Nichols, WW; Nordmann, P; Rossolini, GM; Seifert, H; Stefanik, D; Testa, R, 2015)	0.81
"Avibactam is a novel non-β-lactam β-lactamase inhibitor effective against Ambler class A, C and some class D β-lactamases that is currently in clinical development in combination with ceftazidime for the treatment of serious Gram-negative infections."	( Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies. Merdjan, H; Rangaraju, M; Tarral, A, 2015)	2.09
" Avibactam, a non-β-lactam β-lactamase inhibitor, has been combined with ceftaroline or ceftazidime but these two combinations have not been directly compared."	( The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection. Bowker, K; MacGowan, A; Noel, A; Tomaselli, S, 2017)	1.67
"The in vitro activity of anti-pseudomonal β-lactams in combination with avibactam was evaluated against 54 multidrug-resistant non-fermenting Gram-negative bacilli isolated from cystic fibrosis patients."	( In vitro activity of β-lactams in combination with avibactam against multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Achromobacter xylosoxidans isolates from patients with cystic fibrosis. Compain, F; Grohs, P; Mathy, V, 2018)	0.97
" The aim of this study was to evaluate the in vitro susceptibility of CAZ-AVI alone and in combination with fosfomycin and carbapenems against KPC-Kp clinical isolates by E-test method."	( In Vitro Activity of Ceftazidime/Avibactam Alone and in Combination With Fosfomycin and Carbapenems Against KPC-producing Klebsiella Pneumoniae. Carone, G; Dalfino, L; De Robertis, A; Del Prete, R; Mosca, A; Romanelli, F; Stufano, M, 2020)	0.84
"To evaluate the in vitro activity of aztreonam in combination with novel β-lactamase inhibitors, namely avibactam, nacubactam, taniborbactam and zidebactam, against MDR MBL-producing Enterobacterales and Pseudomonas aeruginosa clinical isolates."	( In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases. Le Terrier, C; Nordmann, P; Poirel, L, 2022)	0.94
" This study investigated the activity of aztreonam in combination with novel β-lactamase inhibitors (BLIs) against a national multi-centre study collection of strains co-producing MBLs and SBLs."	( Activity of aztreonam in combination with novel β-lactamase inhibitors against metallo-β-lactamase-producing Enterobacterales from Spain. Alonso-Garcia, I; Álvarez-Fraga, L; Arca-Suárez, J; Beceiro, A; Bou, G; Cendón-Esteve, A; Guijarro-Sánchez, P; Lasarte-Monterrubio, C; Maceiras, R; Martínez-Guitián, M; Outeda, M; Peña-Escolano, A; Vázquez-Ucha, JC, 2023)	0.91
"Evaluate the in vivo efficacy and resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam and meropenem using human-simulated regimens (HSR) in the murine infection model."	( In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii. Echols, R; Gill, CM; Longshaw, C; Nicolau, DP; Santini, D; Takemura, M; Yamano, Y, 2023)	1.35
" In this study, we analyzed the in vitro activity of those novel antibacterial agents alone or in combination with polymyxin B against the CR-A."	( In vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam alone or in combination with polymyxin B against carbapenem resistant Acinetobacter baumannii. Gu, Y; Hu, D; Hu, M; Liang, R; Wang, D; Wang, M; Zhu, M, 2023)	1.19
"The broad synergistic in vitro activity of ceftazidime/avibactam and fosfomycin confirms the potential of the application of this drug combination in clinics."	( Evaluation of in vitro pharmacodynamic drug interactions of ceftazidime/avibactam and fosfomycin in Escherichia coli. Decousser, JW; Grégoire, N; Kroemer, N; Martens, M; Nordmann, P; Wicha, SG, 2023)	1.39
" The aim of this study was to investigate the clinical characteristics and outcomes of patients with CR-GNB infections treated with ceftazidime/avibactam (CAZ/AVI) combined with colistin from October 2019 to February 2023 in China."	( Ceftazidime/avibactam combined with colistin: a novel attempt to treat carbapenem-resistant Gram-negative bacilli infection. Gong, F; Liu, J; Lu, L; Shao, Z; Shi, K; Tang, S; Zheng, Z, 2023)	1.49
"Thirty-one patients were treated with CAZ/AVI combined with colistin."	( Ceftazidime/avibactam combined with colistin: a novel attempt to treat carbapenem-resistant Gram-negative bacilli infection. Gong, F; Liu, J; Lu, L; Shao, Z; Shi, K; Tang, S; Zheng, Z, 2023)	1.29

Excerpt	Reference	Relevance
" Part 2 assessed bioavailability of avibactam after a single oral dose (500 mg) relative to a single 30-min intravenous infusion (500 mg)."	( Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies. Merdjan, H; Rangaraju, M; Tarral, A, 2015)	0.93
" Herein, we describe the synthesis and testing of the first approved BLI to be rendered orally bioavailable since clavulanic acid (1984)."	( Orally Absorbed Derivatives of the β-Lactamase Inhibitor Avibactam. Design of Novel Prodrugs of Sulfate Containing Drugs. Duncton, MAJ; Gallop, MA; Gordon, EM, 2018)	0.73
" Reported here is a novel, orally bioavailable diazabicyclooctane (DBO) β-lactamase inhibitor."	( Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases. Carter, NM; Chen, A; Chen, Y; Comita-Prevoir, J; Durand-Réville, TF; Giacobbe, RA; Lahiri, SD; May-Dracka, TL; McLeod, SM; Miller, AA; Mueller, JP; O'Donnell, JP; Romero, JAC; Sacco, MD; Shapiro, AB; Tommasi, RA; Verheijen, JC; Wu, F; Wu, X; Zhang, J, 2020)	0.56

Excerpt	Relevance	Reference
" This combination dosing regimen should allow for optimal bacterial cell kill (highest likelihood of successful clinical outcome) and the suppression of resistance emergence."	( Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases. Brown, D; Castanheira, M; Critchley, I; Drusano, GL; Grasso, C; Jones, RN; Kulawy, R; Liu, W; Louie, A; Thye, D; Vanscoy, B; Williams, G, 2012)	0.38
" A humanized aztreonam dose of 2 g every 6 h (1-h infusion) was evaluated alone and in combination with avibactam at 375 or 600 mg every 6 h (1-h infusion), targeting the percentage of the dosing interval in which free-drug concentrations remained above the MIC (fT>MIC)."	( Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers. Crandon, JL; Nicolau, DP, 2013)	0.86
"5 g avibactam every 8 h administered as a 2-h infusion or a ceftazidime regimen that produced a specific epithelial lining fluid (ELF) percentage of the dosing interval in which serum free drug concentrations remain above the MIC (fT>MIC) against 28 Pseudomonas aeruginosa isolates within a neutropenic murine pneumonia model and to assess the impact of host infection on pulmonary pharmacokinetics."	( Efficacies of ceftazidime-avibactam and ceftazidime against Pseudomonas aeruginosa in a murine lung infection model. Crandon, JL; Housman, ST; Nichols, WW; Nicolau, DP, 2014)	1.26
" Our discussion includes the importance of selecting the appropriate partner β-lactam and dosing regimens for these promising agents."	( New β-lactamase inhibitors: a therapeutic renaissance in an MDR world. Bonomo, RA; Drawz, SM; Papp-Wallace, KM, 2014)	0.4
" However, the small differences observed between the young and elderly cohorts are not sufficient to warrant dosing adjustments based on age."	( Effect of age and sex on the pharmacokinetics and safety of avibactam in healthy volunteers. Merdjan, H; Tarral, A, 2015)	0.66
" After a 7-day washout, subjects in the 250 and 500 mg dosing groups received a second avibactam dose with concomitant ceftazidime 1000 or 2000 mg, respectively."	( Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies. Merdjan, H; Rangaraju, M; Tarral, A, 2015)	0.87
"Avibactam was generally well tolerated across all dosing regimens, when given alone or with ceftazidime."	( Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies. Merdjan, H; Rangaraju, M; Tarral, A, 2015)	2.09
"Six clinical Enterobacteriaceae isolates expressing MBLs and ESBLs were studied in an in vitro hollow-fibre infection model (HFIM) using various dosing regimens simulating human-like PK for aztreonam/avibactam."	( Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam. Bradford, PA; Eakin, AE; Harris, JJ; Kim, A; McLaughlin, RE; O'Donnell, JP; Patey, S; Singh, R; Tanudra, MA, 2015)	0.81
"The aim of this Phase 1, open-label study (NCT01395420) was to measure and compare concentrations of ceftazidime and avibactam in bronchial epithelial lining fluid (ELF) and plasma, following administration of two different dosing regimens in healthy subjects."	( Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens. Armstrong, J; Das, S; Edeki, T; Learoyd, M; Li, J; Nicolau, DP; Siew, L, 2015)	0.86
" To determine optimal dosing combinations of ceftazidime-avibactam for treating infections with ceftazidime-resistant Pseudomonas aeruginosa, pharmacodynamic responses were explored in murine neutropenic thigh and lung infection models."	( Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection. Berkhout, J; Lagarde, CM; Melchers, MJ; Mouton, JW; Nichols, WW; Schuck, VJ; Seyedmousavi, S; van Mil, AC, 2016)	0.95
" Both ceftolozane/tazobactam and ceftazidime/avibactam are only available as intravenous formulations and are dosed 3 times daily in patients with normal renal function."	( Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations. Bonomo, RA; van Duin, D, 2016)	1.07
" Ceftazidime and avibactam ELF exposures exceeded their respective plasma PK/PD time-above-threshold targets by the dosing interval mid-point in most subjects."	( Population Pharmacokinetic Modelling of Ceftazidime and Avibactam in the Plasma and Epithelial Lining Fluid of Healthy Volunteers. Das, S; Dimelow, R; MacPherson, M; Newell, P; Wright, JG, 2018)	1.07
" Based on the review of the data, the pharmacokinetics of avibactam was generally stationary in the studied dosing regimen."	( Review of Clinical Pharmacokinetics of Avibactam, A Newly Approved non-β lactam β-lactamase Inhibitor Drug, In Combination Use With Ceftazidime. Giri, P; Patel, H; Srinivas, NR, 2019)	1.03
" aeruginosa was used to simulate bacterial responses to modelled human exposures from fractionated avibactam dosing regimens with a fixed ceftazidime dosing regimen (2 or 8 g q8h as a 2-h infusion)."	( A model-based analysis of pharmacokinetic-pharmacodynamic (PK/PD) indices of avibactam against Pseudomonas aeruginosa. Derendorf, H; Nichols, WW; Schuck, VJ; Sy, SKB; Xia, H; Zhuang, L, 2019)	0.96
"To develop a novel mechanism-based pharmacokinetic-pharmacodynamic (PKPD) model for ceftazidime/avibactam against Gram-negative pathogens, with the potential for combination dosage simulation."	( A novel mechanism-based pharmacokinetic-pharmacodynamic (PKPD) model describing ceftazidime/avibactam efficacy against β-lactamase-producing Gram-negative bacteria. Bissantz, C; Haldimann, A; Kristoffersson, AN; Nielsen, EI; Okujava, R; Shi, T; Walter, I; Zampaloni, C, 2020)	1
" A PKPD model was developed and evaluated using internal and external evaluation, and combined with a population PK model and applied in dosage simulations."	( A novel mechanism-based pharmacokinetic-pharmacodynamic (PKPD) model describing ceftazidime/avibactam efficacy against β-lactamase-producing Gram-negative bacteria. Bissantz, C; Haldimann, A; Kristoffersson, AN; Nielsen, EI; Okujava, R; Shi, T; Walter, I; Zampaloni, C, 2020)	0.78
" The model could describe an extensive external Pseudomonas aeruginosa data set with minor modifications to the enhancer effect, and the utility of the model for clinical dosage simulation was demonstrated by investigating the influence of the addition of avibactam."	( A novel mechanism-based pharmacokinetic-pharmacodynamic (PKPD) model describing ceftazidime/avibactam efficacy against β-lactamase-producing Gram-negative bacteria. Bissantz, C; Haldimann, A; Kristoffersson, AN; Nielsen, EI; Okujava, R; Shi, T; Walter, I; Zampaloni, C, 2020)	0.96
" pneumoniae ARLG-1002 (blaNDM-1, blaCTXM-15, blaDHA, blaSHV, blaTEM) were studied in the HFIM using simulated human dosing regimens of ceftazidime/avibactam and aztreonam."	( Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model. Boissonneault, KR; Bonomo, RA; Bulitta, JB; Chambers, HF; Eakin, AE; Fowler, VG; Holden, PN; Lodise, TP; O'Donnell, N; Smith, NM; Tao, X; Tsuji, BT; Zhou, J, 2020)	0.99
" In the prospective validation experiments, ceftazidime/avibactam with aztreonam dosed every 8 and 6 h, respectively (ceftazidime/avibactam 2/0."	( Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model. Boissonneault, KR; Bonomo, RA; Bulitta, JB; Chambers, HF; Eakin, AE; Fowler, VG; Holden, PN; Lodise, TP; O'Donnell, N; Smith, NM; Tao, X; Tsuji, BT; Zhou, J, 2020)	1.03
" The best-fit parameter values were used to predict %T > MICi associated with CAZ/AVI exposures expected in peritoneal fluid after standard dosing (2."	( MIC profiling of ceftazidime/avibactam against two carbapenemase-producing Klebsiella pneumoniae isolates. Eales, BM; Lasco, TM; Merlau, PR; Sofjan, AK; Tam, VH; Wang, W; Zidaru, A, 2020)	0.85
" This case illustrates the importance of TDM, and the logistical issues encountered with the use of alternative dosing strategies in pediatric patients with CF."	( Optimization of Aztreonam in Combination With Ceftazidime/Avibactam in a Cystic Fibrosis Patient With Chronic Stenotrophomonas maltophilia Pneumonia Using Therapeutic Drug Monitoring: A Case Study. Cowart, MC; Ferguson, CL, 2021)	0.87
" Optimal dosing of aztreonam with avibactam is not well-defined in critically ill patients and contingent on ceftazidime/avibactam product labelling."	( Pragmatic options for dose optimization of ceftazidime/avibactam with aztreonam in complex patients. Baldelli, S; Cattaneo, D; Di Paolo, A; Falcone, M; Galfo, V; Leonildi, A; Menichetti, F; Pai, MP; Tagliaferri, E; Tiseo, G, 2021)	1.15
"To identify a pragmatic dosing strategy for aztreonam with avibactam to maximize the probability of target attainment (PTA)."	( Pragmatic options for dose optimization of ceftazidime/avibactam with aztreonam in complex patients. Baldelli, S; Cattaneo, D; Di Paolo, A; Falcone, M; Galfo, V; Leonildi, A; Menichetti, F; Pai, MP; Tagliaferri, E; Tiseo, G, 2021)	1.11
" Population pharmacokinetic (PK) analysis coupled with Monte Carlo simulations were used to create a dosing nomogram for aztreonam and ceftazidime/avibactam based on drug-specific pharmacodynamic (PD) targets."	( Pragmatic options for dose optimization of ceftazidime/avibactam with aztreonam in complex patients. Baldelli, S; Cattaneo, D; Di Paolo, A; Falcone, M; Galfo, V; Leonildi, A; Menichetti, F; Pai, MP; Tagliaferri, E; Tiseo, G, 2021)	1.07
" For aztreonam/avibactam dosing regimens evaluated in clinical trials, fT>MPC values were >90% and >80%, whereas fTMSW measures were <10% and <20% in plasma and ELF, respectively."	( Aztreonam/avibactam effect on pharmacodynamic indices for mutant selection of Escherichia coli and Klebsiella pneumoniae harbouring serine- and New Delhi metallo-β-lactamases. Dong, D; Feng, K; Gong, H; Jia, N; Liu, Y; Lv, Z; Martins, FS; Sy, S; Sy, SKB; Yu, M; Zhang, J; Zhu, P; Zhu, S; Zhu, Y, 2021)	1.38
" Extensive population pharmacokinetic (PK) data sets for ceftazidime and avibactam obtained during the adult clinical development program were used to iteratively select, modify, and validate the approved adult dosage regimen (2,000-500 mg by 2-hour intravenous (IV) infusion every 8 hours (q8h), with adjustments for renal function)."	( Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime-Avibactam in Pediatric Patients Aged 3 Months and Older. Bradley, JS; Carrothers, TJ; Chan, PLS; Franzese, RC; Lovern, M; McFadyen, L; Raber, S; Riccobene, T; Vourvahis, M; Watson, KJ, 2022)	1.17
" Therapeutic drug monitoring (TDM) is urgently needed to optimize dosage regimens to maximize efficacy, minimize toxicity, and delay the emergence of resistance."	( Rapid, simple, and economical LC-MS/MS method for simultaneous determination of ceftazidime and avibactam in human plasma and its application in therapeutic drug monitoring. Cai, Y; Chen, M; Cheng, Y; Li, X; Lin, H; Liu, M; Qiu, H; Que, W; Zhang, B; Zhang, H, 2022)	0.94
" aeruginosa, quantitative reductions in bacterial density observed with the translational murine model suggest that the phenotypic profile of ceftazidime, ceftazidime/avibactam and meropenem is predictive of clinical efficacy when using the evaluated dosing regimens."	( In vivo translational assessment of the GES genotype on the killing profile of ceftazidime, ceftazidime/avibactam and meropenem against Pseudomonas aeruginosa. Fraile-Ribot, PA; Gill, CM; Nicolau, DP; Oliver, A, 2022)	1.13
"The objective of this pharmacokinetic (PK)/pharmacodynamic (PD) analysis was to evaluate the efficacy of different dosing regimens of ceftazidime/avibactam (CZA) for the treatment of pulmonary infections by extensively drug-resistant (XDR) Pseudomonas aeruginosa using optimized two-step administration therapy (OTAT) and traditional infusion (TI)."	( Evaluation of the Efficacy of Optimized Two-Step-Administration Therapy with Ceftazidime/Avibactam for Treating Extensively Drug-Resistant Pseudomonas aeruginosa Pulmonary Infections: a Pharmacokinetic/Pharmacodynamic Analysis. Cui, J; Kang, Y, 2023)	1.33
" We used a novel framework to provide insights of optimal dosing exposure of ceftazidime/avibactam."	( Optimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniae. Eales, BM; Hudson, CS; Kline, EG; Merlau, PR; Shields, RK; Smith, J; Sofjan, AK; Tam, VH, 2022)	1.27
" Using the best-fit parameter values, %fT>MICi was estimated for various dosing regimens of ceftazidime/avibactam."	( Optimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniae. Eales, BM; Hudson, CS; Kline, EG; Merlau, PR; Shields, RK; Smith, J; Sofjan, AK; Tam, VH, 2022)	1.26
" The novel framework is informative and may be used to guide optimal dosing of other β-lactam/β-lactamase inhibitor combinations."	( Optimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniae. Eales, BM; Hudson, CS; Kline, EG; Merlau, PR; Shields, RK; Smith, J; Sofjan, AK; Tam, VH, 2022)	1.04
"The present report firstly described a critically ill patient receiving a dosing regimen of ceftazidime-avibactam (CAZ-AVI) (1."	( A therapeutic regimen of ceftazidime-avibactam for a critical patient receiving prolonged intermittent renal replacement therapy. Cao, XY; Chen, SY; Jin, Y; Liu, WH; Ni, M; Qiu, YS; Shen, CR; Shen, FM; Yan, YY, 2023)	1.4

Role	Description
antibacterial drug	A drug used to treat or prevent bacterial infections.
antimicrobial agent	A substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
EC 3.5.2.6 (beta-lactamase) inhibitor	An EC 3.5.2.* (non-peptide cyclic amide C-N hydrolase) inhibitor that interferes with the action of beta-lactamase (EC 3.5.2.6).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
monocarboxylic acid amide	A carboxamide derived from a monocarboxylic acid.
ureas
azabicycloalkane
hydroxylamine O-sulfonic acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Beta-lactamase	Escherichia coli	Ki	0.0110	0.0110	0.0335	0.0560	AID1657152
Beta-lactamase	Enterobacter cloacae	IC50 (µMol)	0.1000	0.1000	1.8745	7.7000	AID584977
Beta-lactamase	Enterobacter cloacae	Ki	7.7000	7.3000	7.5000	7.7000	AID584988
Beta-lactamase	Pseudomonas aeruginosa PAO1	IC50 (µMol)	0.1280	0.1280	1.6916	4.6000	AID584978
Beta-lactamase TEM	Escherichia coli	IC50 (µMol)	0.0019	0.0019	1.7618	10.0000	AID1758321
Beta-lactamase	Acinetobacter baumannii	Ki	1.7000	1.7000	1.7000	1.7000	AID1657160
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Beta-lactamase	Enterobacter cloacae	K	5.1000	5.1000	5.1000	5.1000	AID584990
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Assay ID	Title	Year	Journal	Article
AID1657157	Inhibition of recombinant Escherichia coli SHV-12 using nitrocefin as substrate preincubated for 10 mins followed by substrate addition measured every 10 secs for 10 mins by spectrophotometrically analysis	2020	Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14	Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases.
AID584982	Ratio of Kinact/K for Enterobacter cloacae beta-lactamase P99 by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID1559343	Inhibition of KPC-2/SHV12/TEM-1 in Klebsiella pneumoniae CDC-0361 assessed as meropenem antibacterial activity at 4 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 16 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1525996	Inhibition of NDM-1 in Escherichia coli 5980 assessed as potentiation of ceftazidime-induced antimicrobial activity by measuring ceftazidime MIC incubated for 18 to 20 hrs by CLSI based method	2019	Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18	Heteroaryl Phosphonates as Noncovalent Inhibitors of Both Serine- and Metallocarbapenemases.
AID1740625	Inhibition of beta lactamase P99 in Enterobacter cloacae assessed as ratio of Kinact/Ki using nitrocefin as chromogenic substrate by fluorescence plate reader analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases.
AID1559333	Inhibition of OXA-232/OXA-9/TEM-1A/CTX-M-15/OXA-1 in Klebsiella pneumoniae CDC-0066 assessed as cefepime antibacterial activity at 8 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb > 128 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1559320	Inhibition of bacterial NDM-1 using cefepime as substrate preincubated for 15 mins followed by susbtrate addition and measured after 10 mins by spectrophotometric method	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1740604	Inhibition of beta lactamase TEM-1 in Escherichia coli assessed as decrease in enzyme activity using nitrocefin as chromogenic substrate incubated for 60 mins by fluorescence plate reader analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases.
AID1559337	Inhibition of KPC-2/PDC-42 in Pseudomonas aeruginosa CDC-0457 assessed as cefepime antibacterial activity at 8 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 16 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1559340	Inhibition of NDM-1/CMY-6/OXA-1 in Escherichia coli CDC-0055 assessed as meropenem antibacterial activity at 4 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 32 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1559311	Inhibition of bacterial VIM-2 using nitrocefin as substrate preincubated for 15 mins followed by susbtrate addition and measured after 10 mins by spectrophotometric method	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1559403	Volume of distribution at steady state in mouse at 10 mg/kg, iv after 1 to 6 hrs by LC-MS/MS analysis	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1657168	Inhibition of Klebsiella pneumoniae KP1081 NDM-1 assessed as minimum concentration of compound required to reduce the MIC of biapenem to 1 ug/ml	2020	Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14	Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases.
AID1559323	Inhibition of VIM-27/CTX-M-15/SHV-11/OXA-1 in Klebsiella pneumoniae CDC-0040 assessed as piperacillin antibacterial activity at 16 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb > 128 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1559353	Inhibition of VIM-1/VIM-2/VIM-4/NDM-1 in Escherichia coli assessed as cefepime antibacterial activity at 4 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 32 to 512 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1740603	Inhibition of beta lactamase TEM-1 in Escherichia coli assessed as decrease in enzyme activity using nitrocefin as chromogenic substrate incubated for 10 mins by fluorescence plate reader analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases.
AID1701469	Antibacterial activity against Acinetobacter baumannii expressing OXA-23 by broth microdilution method	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Discovery of
AID1559310	Inhibition of bacterial OXA-48 using nitrocefin as substrate preincubated for 15 mins followed by susbtrate addition and measured after 10 mins by spectrophotometric method	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID584988	Inhibition of Enterobacter cloacae beta-lactamase P99 after 5 seconds incubation with nitrocefin substrate by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID1740627	Inhibition of bacterial OXA-23 assessed as ratio of Kinact/Ki using nitrocefin as chromogenic substrate by fluorescence plate reader analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases.
AID1559338	Inhibition of KPC-2 in Klebsiella pneumoniae ATCC BAA 1705 assessed as meropenem antibacterial activity at 4 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 16 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1740608	Inhibition of beta lactamase OXA-48 in Klebsiella pneumoniae assessed as decrease in enzyme activity using nitrocefin as chromogenic substrate incubated for 60 mins by fluorescence plate reader analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases.
AID1740619	Inhibition of bacterial CTX-M-14 assessed as ratio of Kinact/Ki using nitrocefin as chromogenic substrate by fluorescence plate reader analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases.
AID1559355	Inhibition of VIM-1/VIM-2/VIM-4/NDM-1 in Klebsiella pneumoniae assessed as cefepime antibacterial activity at 4 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 32 to 512 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1559319	Inhibition of bacterial OXA-1 using nitrocefin as substrate preincubated for 15 mins followed by susbtrate addition and measured after 10 mins by spectrophotometric method	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1657244	Inhibition of Klebsiella pneumoniae KP1081 NDM-1 assessed as minimum concentration of compound needed to reduce the MIC of biapenem to 1 ug/ml	2020	Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14	Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases.
AID1559354	Inhibition of VIM-1/VIM-2/VIM-4/NDM-1 in Enterobacter cloacae assessed as cefepime antibacterial activity at 4 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 32 to 512 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1740626	Inhibition of bacterial OXA-10 assessed as ratio of Kinact/Ki using nitrocefin as chromogenic substrate by fluorescence plate reader analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases.
AID1701462	Potentiation of meropenem-induced antibacterial activity against Klebsiella pneumoniae expressing TEM-1/SHV-11/KPC-3 assessed as meropenem MIC at 4 ug/ml by broth microdilution method (Rvb = 128 ug/ml)	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Discovery of
AID1740629	Inhibition of bacterial OXA-48 assessed as ratio of Kinact/Ki using nitrocefin as chromogenic substrate by fluorescence plate reader analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases.
AID1559341	Inhibition of OXA-232/OXA-9/TEM-1A/CTX-M-15/OXA-1 in Klebsiella pneumoniae CDC-0066 assessed as meropenem antibacterial activity at 4 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 32 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1758320	Inhibition of bacterial Beta-lactamase KPC-2 (29 - 289) (unknown origin) expressed in Escherichia coli Transetta (DE3)	2021	Bioorganic & medicinal chemistry letters, 06-01, Volume: 41	Discovery of 3-aryl substituted benzoxaboroles as broad-spectrum inhibitors of serine- and metallo-β-lactamases.
AID1649583	Antimicrobial activity against Klebsiella pneumoniae clinical isolates by standard broth microdilution method	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	A γ-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli.
AID1657152	Inhibition of recombinant Escherichia coli KPC-2 using nitrocefin as substrate preincubated for 10 mins followed by substrate addition and measured every 10 secs for 10 mins by spectrophotometric analysis	2020	Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14	Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases.
AID584973	Inhibition of beta-lactamase SHV-4 assessed as nitrocefin hydrolysis after 5 mins enzyme-compound preincubation	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID584979	Inhibition of beta-lactamase TEM-1 assessed as inactivation rate constant by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID1758325	Inhibition of bacterial Beta-lactamase VIM-1 (27 - 266) (unknown origin) expressed in Escherichia coli Transetta (DE3)	2021	Bioorganic & medicinal chemistry letters, 06-01, Volume: 41	Discovery of 3-aryl substituted benzoxaboroles as broad-spectrum inhibitors of serine- and metallo-β-lactamases.
AID1657160	Inhibition of Acinetobacter baumannii OXA-23 using nitrocefin as substrate preincubated for 10 mins followed by substrate addition measured every 10 secs for 10 mins by spectrophotometrically analysis	2020	Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14	Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases.
AID1657241	Inhibition of Klebsiella pneumoniae KP1004 KPC-2 assessed as minimum concentration of compound needed to reduce the MIC of biapenem to 1 ug/ml	2020	Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14	Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases.
AID1559339	Inhibition of VIM-27/CTX-M-15/SHV-11/OXA-1 in Klebsiella pneumoniae CDC-0040 assessed as meropenem antibacterial activity at 4 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb > 128 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1559309	Inhibition of bacterial AmpC using nitrocefin as substrate preincubated for 15 mins followed by susbtrate addition and measured after 10 mins by spectrophotometric method	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1758326	Inhibition of bacterial Beta-lactamase SFH-1 (3 - 234) expressed in Escherichia coli Transetta (DE3)	2021	Bioorganic & medicinal chemistry letters, 06-01, Volume: 41	Discovery of 3-aryl substituted benzoxaboroles as broad-spectrum inhibitors of serine- and metallo-β-lactamases.
AID1559357	Inhibition of VIM-1/VIM-2/VIM-4/NDM-1 in Acinetobacter baumannii assessed as cefepime antibacterial activity at 4 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 32 to 512 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1559328	Inhibition of NDM in Escherichia coli CDC-0452 assessed as piperacillin antibacterial activity at 16 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb > 128 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1740622	Inhibition of bacterial SHV-5 assessed as ratio of Kinact/Ki using nitrocefin as chromogenic substrate by fluorescence plate reader analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases.
AID1701453	Half life in rat at 1 mg/kg, iv	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Discovery of
AID1701463	Potentiation of meropenem-induced antibacterial activity against Klebsiella pneumoniae expressing SHV-11/OXA-121 assessed as meropenem MIC at 4 ug/ml by broth microdilution method (Rvb = 16 ug/ml)	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Discovery of
AID1526000	Inhibition of VIM-2 in Pseudomonas aeruginosa 4698 assessed as potentiation of ceftazidime-induced antimicrobial activity by measuring ceftazidime MIC incubated for 18 to 20 hrs by CLSI based method	2019	Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18	Heteroaryl Phosphonates as Noncovalent Inhibitors of Both Serine- and Metallocarbapenemases.
AID1657162	Inhibition of recombinant Escherichia coli IMP-1 using imipenem as substrate preincubated for 10 mins followed by substrate addition measured every 30 secs for 30 mins by spectrophotometrically analysis	2020	Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14	Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases.
AID1740607	Inhibition of beta lactamase OXA-48 in Klebsiella pneumoniae assessed as decrease in enzyme activity using nitrocefin as chromogenic substrate incubated for 10 mins by fluorescence plate reader analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases.
AID1559318	Inhibition of bacterial CMY-2 using nitrocefin as substrate preincubated for 15 mins followed by susbtrate addition and measured after 10 mins by spectrophotometric method	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1740606	Inhibition of beta lactamase AmpC in Pseudomonas aeruginosa assessed as decrease in enzyme activity using nitrocefin as chromogenic substrate incubated for 60 mins by fluorescence plate reader analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases.
AID1559321	Inhibition of bacterial IMP-1 using nitrocefin as substrate preincubated for 15 mins followed by susbtrate addition and measured after 10 mins by spectrophotometric method	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1657159	Inhibition of Acinetobacter baumannii OXA-48 using nitrocefin as substrate preincubated for 10 mins followed by substrate addition measured every 10 secs for 10 mins by spectrophotometrically analysis	2020	Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14	Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases.
AID584980	Inhibition of Enterobacter cloacae beta-lactamase P99 assessed as inactivation rate constant by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID1677277	Potentiation of aztreonam-induced antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa 88949 clinical isolate assessed as fold reduction in aztreonam MIC at 8 uM	2020	Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21	Overcoming β-Lactam resistance in Pseudomonas aeruginosa using non-canonical tobramycin-based antibiotic adjuvants.
AID1657158	Inhibition of recombinant Escherichia coli AmpC using nitrocefin as substrate preincubated for 10 mins followed by substrate addition measured every 10 secs for 10 mins by spectrophotometrically analysis	2020	Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14	Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases.
AID1758324	Inhibition of bacterial New Delhi metallo-beta-lactamase 1 (1- 270) (unknown origin) expressed in Escherichia coli Transetta (DE3)	2021	Bioorganic & medicinal chemistry letters, 06-01, Volume: 41	Discovery of 3-aryl substituted benzoxaboroles as broad-spectrum inhibitors of serine- and metallo-β-lactamases.
AID1740628	Inhibition of bacterial OXA-24 assessed as ratio of Kinact/Ki using nitrocefin as chromogenic substrate by fluorescence plate reader analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases.
AID1559331	Inhibition of VIM-27/CTX-M-15/SHV-11/OXA-1 in Klebsiella pneumoniae CDC-0040 assessed as cefepime antibacterial activity at 8 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb > 128 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1649582	Antimicrobial activity against Pseudomonas aeruginosa clinical isolates by standard broth microdilution method	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	A γ-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli.
AID1559334	Inhibition of KPC-2/PDC-42 in Pseudomonas aeruginosa CDC-0356 assessed as cefepime antibacterial activity at 8 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb > 128 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1701504	Clearance in rat at 1 mg/kg, iv	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Discovery of
AID1701466	Antibacterial activity against Klebsiella pneumoniae expressing TEM-OSBL/CTX-M-14/OXA-48 by broth microdilution method	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Discovery of
AID584978	Inhibition of Pseudomonas aeruginosa beta-lactamase AmpC assessed as nitrocefin hydrolysis after 5 mins enzyme-compound preincubation	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID1701468	Antibacterial activity against Klebsiella pneumoniae expressing SHV-11/OXA-181 by broth microdilution method	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Discovery of
AID1559324	Inhibition of NDM-1/CMY-6/OXA-1 in Escherichia coli CDC-0055 assessed as piperacillin antibacterial activity at 16 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb > 128 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1740630	Inhibition of Escherichia coli PBP2 assessed as ratio of Kinact/Ki by SDS-PAGE based fluorescence assay	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases.
AID584977	Inhibition of Enterobacter cloacae beta-lactamase P99 assessed as nitrocefin hydrolysis after 5 mins enzyme-compound preincubation	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID1740610	Antibacterial activity against Klebsiella pneumoniae ARC561 assessed as reduction in bacterial growth by CLSI based broth dilution method	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases.
AID1677276	Potentiation of aztreonam-induced antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa 107092 clinical isolate assessed as fold reduction in aztreonam MIC at 8 uM	2020	Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21	Overcoming β-Lactam resistance in Pseudomonas aeruginosa using non-canonical tobramycin-based antibiotic adjuvants.
AID1701464	Potentiation of meropenem-induced antibacterial activity against Acinetobacter baumannii expressing OXA-23 assessed as meropenem MIC at 4 ug/ml by broth microdilution method (Rvb = 32 ug/ml)	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Discovery of
AID1559401	Half life in mouse at 10 mg/kg, iv after 1 to 6 hrs by LC-MS/MS analysis	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1740609	Antibacterial activity against Escherichia coli ARC3627 assessed as reduction in bacterial growth by CLSI based broth dilution method	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases.
AID1525999	Inhibition of NDM-1 in Enterobacter cloacae 5981 assessed as potentiation of ceftazidime-induced antimicrobial activity by measuring ceftazidime MIC incubated for 18 to 20 hrs by CLSI based method	2019	Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18	Heteroaryl Phosphonates as Noncovalent Inhibitors of Both Serine- and Metallocarbapenemases.
AID1677272	Potentiation of ceftazidime-induced antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa 88949 clinical isolate assessed as fold reduction in ceftazidime MIC at 8 uM	2020	Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21	Overcoming β-Lactam resistance in Pseudomonas aeruginosa using non-canonical tobramycin-based antibiotic adjuvants.
AID1559336	Inhibition of NDM in Escherichia coli CDC-0452 assessed as cefepime antibacterial activity after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 64 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1758323	Inhibition of bacterial Beta-lactamase OXA-48 (1 - 265) (unknown origin) expressed in Escherichia coli Transetta (DE3)	2021	Bioorganic & medicinal chemistry letters, 06-01, Volume: 41	Discovery of 3-aryl substituted benzoxaboroles as broad-spectrum inhibitors of serine- and metallo-β-lactamases.
AID1740605	Inhibition of beta lactamase AmpC in Pseudomonas aeruginosa assessed as decrease in enzyme activity using nitrocefin as chromogenic substrate incubated for 10 mins by fluorescence plate reader analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases.
AID1578811	Inhibition of beta-lactamase TEM-4 in Klebsiella pneumoniae 25637 assessed as potentiation of ceftazidime-induced antibacterial activity by measuring ceftazidime MIC (Rvb = 32 ug/ml)	2019	Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19	Antibiotic Adjuvants: Make Antibiotics Great Again!
AID1559326	Inhibition of KPC-2/PDC-42 in Pseudomonas aeruginosa CDC-0356 assessed as piperacillin antibacterial activity at 16 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb > 128 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1758321	Inhibition of bacterial Beta-lactamase TEM-1 (24 - 286) (unknown origin) expressed in Escherichia coli Transetta (DE3)	2021	Bioorganic & medicinal chemistry letters, 06-01, Volume: 41	Discovery of 3-aryl substituted benzoxaboroles as broad-spectrum inhibitors of serine- and metallo-β-lactamases.
AID1559356	Inhibition of VIM-1/VIM-2/VIM-4/NDM-1 in Pseudomonas aeruginosa assessed as cefepime antibacterial activity at 4 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 32 to 512 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1578814	Inhibition of Beta-lactamase PER-1 in Escherichia coli KB10 assessed as potentiation of ceftazidime-induced antibacterial activity by measuring ceftazidime MIC (Rvb >64 ug/ml)	2019	Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19	Antibiotic Adjuvants: Make Antibiotics Great Again!
AID1525997	Inhibition of KPC2 in Klebsiella pneumoniae 4683 assessed as potentiation of ceftazidime-induced antimicrobial activity by measuring ceftazidime MIC incubated for 18 to 20 hrs by CLSI based method	2019	Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18	Heteroaryl Phosphonates as Noncovalent Inhibitors of Both Serine- and Metallocarbapenemases.
AID1677271	Potentiation of ceftazidime-induced antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa 107092 clinical isolate assessed as fold reduction in ceftazidime MIC at 8 uM	2020	Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21	Overcoming β-Lactam resistance in Pseudomonas aeruginosa using non-canonical tobramycin-based antibiotic adjuvants.
AID1559329	Inhibition of KPC-2/PDC-42 in Pseudomonas aeruginosa CDC-0457 assessed as piperacillin antibacterial activity at 16 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 64 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1657153	Inhibition of recombinant Escherichia coli OXA-48 using nitrocefin as substrate preincubated for 10 mins followed by substrate addition and measured every 10 secs for 10 mins by spectrophotometric analysis	2020	Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14	Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases.
AID1701454	Inhibition of beta lactamase AmpC in Enterobacter cloacae assessed as decrease in enzyme activity using nitrocefin as substrate preincubated for 10 mins followed by substrate addition measured for 10 mins by fluorescence plate reader analysis	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Discovery of
AID584990	Inhibition of Enterobacter cloacae beta-lactamase P99 assessed as dissociation constant by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID1701465	Antibacterial activity against Enterobacter cloacae expressing TEM-1/KPC-2 by broth microdilution method	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Discovery of
AID1559325	Inhibition of OXA-232/OXA-9/TEM-1A/CTX-M-15/OXA-1 in Klebsiella pneumoniae CDC-0066 assessed as piperacillin antibacterial activity at 16 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb > 128 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1578810	Inhibition of beta-lactamase TEM-2 in Klebsiella pneumoniae IP1 assessed as potentiation of ceftazidime-induced antibacterial activity by measuring ceftazidime MIC (Rvb = 16 ug/ml)	2019	Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19	Antibiotic Adjuvants: Make Antibiotics Great Again!
AID1559317	Inhibition of bacterial CTX-M-15 using cefotaxime as substrate preincubated for 15 mins followed by susbtrate addition and measured after 10 mins by spectrophotometric method	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID584987	Inhibition of beta-lactamase TEM-1 after 5 seconds incubation with nitrocefin substrate by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID1559316	Inhibition of bacterial SHV-5 using cefotaxime as substrate preincubated for 15 mins followed by susbtrate addition and measured after 10 mins by spectrophotometric method	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1758322	Inhibition of bacterial Beta-lactamase AmpC (20 - 377) (unknown origin) expressed in Escherichia coli Transetta (DE3)	2021	Bioorganic & medicinal chemistry letters, 06-01, Volume: 41	Discovery of 3-aryl substituted benzoxaboroles as broad-spectrum inhibitors of serine- and metallo-β-lactamases.
AID1559344	Inhibition of NDM in Escherichia coli CDC-0452 assessed as meropenem antibacterial activity at 4 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 32 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1701461	Potentiation of meropenem-induced antibacterial activity against Klebsiella pneumoniae expressing TEM-OSBL/CTX-M-14/OXA-48 assessed as meropenem MIC at 4 ug/ml by broth microdilution method (Rvb = 16 ug/ml)	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Discovery of
AID584975	Inhibition of beta-lactamase CTX-M-15 assessed as nitrocefin hydrolysis after 5 mins enzyme-compound preincubation	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID1559322	Inhibition of KPC-2 in Klebsiella pneumoniae ATCC BAA 1705 assessed as piperacillin antibacterial activity at 16 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb > 128 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1657154	Inhibition of recombinant Escherichia coli NDM-1 using imipenem as substrate preincubated for 10 mins followed by substrate addition and measured every 30 secs for 30 mins by spectrophotometric analysis	2020	Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14	Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases.
AID1677278	Potentiation of aztreonam-induced antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa 86052 clinical isolate assessed as fold reduction in aztreonam MIC at 8 uM	2020	Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21	Overcoming β-Lactam resistance in Pseudomonas aeruginosa using non-canonical tobramycin-based antibiotic adjuvants.
AID1740621	Inhibition of bacterial KPC-2 assessed as ratio of Kinact/Ki using nitrocefin as chromogenic substrate by fluorescence plate reader analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases.
AID1559342	Inhibition of KPC-2/PDC-42 in Pseudomonas aeruginosa CDC-0356 assessed as meropenem antibacterial activity at 4 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 32 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1578813	Inhibition of Beta-lactamase SHV-2 in Klebsiella pneumoniae IP86 assessed as potentiation of ceftazidime-induced antibacterial activity by measuring ceftazidime MIC (Rvb = 64 ug/ml)	2019	Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19	Antibiotic Adjuvants: Make Antibiotics Great Again!
AID1320839	Inhibition of native signal containing Klebsiella pneumoniae OXA-48 at 1.5 uM using nitrocefin substrate pre-incubated for 5 mins before substrate addition	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Screening and Design of Inhibitor Scaffolds for the Antibiotic Resistance Oxacillinase-48 (OXA-48) through Surface Plasmon Resonance Screening.
AID1657155	Inhibition of recombinant Escherichia coli CTX-M-14 using nitrocefin as substrate preincubated for 10 mins followed by substrate addition measured every 10 secs for 10 mins by spectrophotometrically analysis	2020	Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14	Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases.
AID1701460	Potentiation of meropenem-induced antibacterial activity against Enterobacter cloacae expressing TEM-1/KPC-2 assessed as meropenem MIC at 4 ug/ml by broth microdilution method (Rvb = 8 ug/ml)	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Discovery of
AID1740612	Inhibition of beta-lactamase activity in Klebsiella pneumoniae ARC561 assessed as MIC for cefpodoxime antibacterial activity at 4 ug/ml by CLSI based broth dilution method (Rvb = 32 ug/ml)	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases.
AID1559332	Inhibition of NDM-1/CMY-6/OXA-1 in Escherichia coli CDC-0055 assessed as cefepime antibacterial activity at 8 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 128 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1677275	Potentiation of aztreonam-induced antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa 108590 clinical isolate assessed as fold reduction in aztreonam MIC at 8 uM	2020	Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21	Overcoming β-Lactam resistance in Pseudomonas aeruginosa using non-canonical tobramycin-based antibiotic adjuvants.
AID1559402	AUC (infinity) in mouse at 10 mg/kg, iv after 1 to 6 hrs by LC-MS/MS analysis	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1559345	Inhibition of KPC-2/PDC-42 in Pseudomonas aeruginosa CDC-0457 assessed as meropenem antibacterial activity at 4 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 128 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1740620	Inhibition of bacterial CTX-M-15 assessed as ratio of Kinact/Ki using nitrocefin as chromogenic substrate by fluorescence plate reader analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases.
AID1578809	Inhibition of beta-lactamase TEM-1 in Escherichia coli GN5482 assessed as potentiation of ceftazidime-induced antibacterial activity by measuring ceftazidime MIC (Rvb = 4 ug/ml)	2019	Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19	Antibiotic Adjuvants: Make Antibiotics Great Again!
AID1657166	Inhibition of Klebsiella pneumoniae KP1004 KPC-2 assessed as minimum concentration of compound needed to reduce the MIC of aztreonam to 4 ug/ml	2020	Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14	Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases.
AID1677270	Potentiation of ceftazidime-induced antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa 108590 clinical isolate assessed as fold reduction in ceftazidime MIC at 8 uM	2020	Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21	Overcoming β-Lactam resistance in Pseudomonas aeruginosa using non-canonical tobramycin-based antibiotic adjuvants.
AID1578812	Inhibition of beta-lactamase TEM-8 in Escherichia coli CF3 assessed as potentiation of ceftazidime-induced antibacterial activity by measuring ceftazidime MIC (Rvb = 64 ug/ml)	2019	Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19	Antibiotic Adjuvants: Make Antibiotics Great Again!
AID1701455	Inhibition of beta lactamase CTXM-15 in Enterobacter cloacae assessed as decrease in enzyme activity using nitrocefin as substrate preincubated for 10 mins followed by substrate addition measured for 10 mins by fluorescence plate reader analysis	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Discovery of
AID1559404	Clearance in mouse at 190 mg/kg, iv after 1 to 6 hrs by LC-MS/MS analysis	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1559335	Inhibition of KPC-2/SHV12/TEM-1 in Klebsiella pneumoniae CDC-0361 assessed as cefepime antibacterial activity at 8 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 32 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID584974	Inhibition of beta-lactamase KPC-2 assessed as nitrocefin hydrolysis after 5 mins enzyme-compound preincubation	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID1701457	Inhibition of beta lactamase OXA-48 in Enterobacter cloacae assessed as decrease in enzyme activity using nitrocefin as substrate preincubated for 10 mins followed by substrate addition measured for 10 mins by fluorescence plate reader analysis	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Discovery of
AID1657156	Inhibition of recombinant Escherichia coli TEM-10 using nitrocefin as substrate preincubated for 10 mins followed by substrate addition measured every 10 secs for 10 mins by spectrophotometrically analysis	2020	Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14	Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases.
AID1701503	AUC in rat at 1 mg/kg, iv	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Discovery of
AID1740624	Inhibition of beta lactamase AmpC in Pseudomonas aeruginosa assessed as ratio of Kinact/Ki using nitrocefin as chromogenic substrate by fluorescence plate reader analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases.
AID1657161	Inhibition of recombinant Escherichia coli VIM-1 using nitrocefin as substrate preincubated for 10 mins followed by substrate addition measured every 10 secs for 10 mins by spectrophotometrically analysis	2020	Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14	Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases.
AID1701456	Inhibition of beta lactamase TEM-1 in Enterobacter cloacae assessed as decrease in enzyme activity using nitrocefin as substrate preincubated for 10 mins followed by substrate addition measured for 10 mins by fluorescence plate reader analysis	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Discovery of
AID1677273	Potentiation of ceftazidime-induced antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa 86052 clinical isolate assessed as fold reduction in ceftazidime MIC at 8 uM	2020	Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21	Overcoming β-Lactam resistance in Pseudomonas aeruginosa using non-canonical tobramycin-based antibiotic adjuvants.
AID1740611	Inhibition of beta-lactamase activity in Escherichia coli ARC3627 assessed as MIC for cefpodoxime antibacterial activity at 4 ug/ml by CLSI based broth dilution method (Rvb >64 ug/ml)	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases.
AID1677274	Potentiation of aztreonam-induced antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa 109084 clinical isolate assessed as fold reduction in aztreonam MIC at 8 uM	2020	Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21	Overcoming β-Lactam resistance in Pseudomonas aeruginosa using non-canonical tobramycin-based antibiotic adjuvants.
AID1701505	Volume of distribution in rat at 1 mg/kg, iv	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Discovery of
AID1525998	Inhibition of NDM-1 in Klebsiella pneumoniae 5979 assessed as potentiation of ceftazidime-induced antimicrobial activity by measuring ceftazidime MIC incubated for 18 to 20 hrs by CLSI based method	2019	Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18	Heteroaryl Phosphonates as Noncovalent Inhibitors of Both Serine- and Metallocarbapenemases.
AID584976	Inhibition of beta-lactamase TEM- 1 assessed as nitrocefin hydrolysis after 5 mins enzyme-compound preincubation	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID1657243	Inhibition of Klebsiella pneumoniae KP1086 OXA-48 assessed as minimum concentration of compound needed to reduce the MIC of biapenem to 1 ug/ml	2020	Journal of medicinal chemistry, 07-23, Volume: 63, Issue:14	Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases.
AID584981	Ratio of Kinact/K for beta-lactamase TEM-1 by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID1559308	Inhibition of bacterial KPC-2 using imipenem as substrate preincubated for 15 mins followed by susbtrate addition and measured after 10 mins by spectrophotometric method	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1559330	Inhibition of KPC-2 in Klebsiella pneumoniae ATCC BAA 1705 assessed as cefepime antibacterial activity at 8 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb = 16 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
AID1677269	Potentiation of ceftazidime-induced antibacterial activity against carbapenem-resistant Pseudomonas aeruginosa 109084 clinical isolate assessed as fold reduction in ceftazidime MIC at 8 uM	2020	Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21	Overcoming β-Lactam resistance in Pseudomonas aeruginosa using non-canonical tobramycin-based antibiotic adjuvants.
AID1701459	Inhibition of bacteria beta lactamase OXA-23 assessed as decrease in enzyme activity using nitrocefin as substrate preincubated for 10 mins followed by substrate addition measured for 10 mins by fluorescence plate reader analysis	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Discovery of
AID584989	Inhibition of beta-lactamase TEM-1 assessed as dissociation constant by spectrophotometry	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID1740623	Inhibition of bacterial TEM-1 assessed as ratio of Kinact/Ki using nitrocefin as chromogenic substrate by fluorescence plate reader analysis	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases.
AID1701467	Antibacterial activity against Klebsiella pneumoniae expressing TEM-1/SHV-11/KPC-3 by broth microdilution method	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Discovery of
AID1701458	Inhibition of beta lactamase KPC-2 in Enterobacter cloacae assessed as decrease in enzyme activity using nitrocefin as substrate preincubated for 10 mins followed by substrate addition measured for 10 mins by fluorescence plate reader analysis	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Discovery of
AID1559327	Inhibition of KPC-2/SHV12/TEM-1 in Klebsiella pneumoniae CDC-0361 assessed as piperacillin antibacterial activity at 16 ug/ml after 16 to 20 hrs by CLSI-based microbroth dilution method (Rvb > 128 ug/ml)	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (0.56)	29.6817
2010's	168 (47.06)	24.3611
2020's	187 (52.38)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	16 (4.44%)	5.53%
Reviews	22 (6.11%)	6.00%
Case Studies	12 (3.33%)	4.05%
Observational	8 (2.22%)	0.25%
Other	302 (83.89%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (42)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of a Single Dose of Intravenous Ceftazidime NXL104 (3000/2000 mg) or Ceftaroline Fosamil NXL104 (1500/2000 mg), Co [NCT01290900]	Phase 1	54 participants (Actual)	Interventional	2011-02-28	Completed
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japa [NCT01291602]	Phase 1	15 participants (Actual)	Interventional	2011-02-28	Completed
Retrospective Analysis to Characterize the Real World Use Patterns, Efficacy and Safety of Ceftazidime-avibactam in the Management of Gram Negative Infections. [NCT04628572]		204 participants (Actual)	Observational	2021-01-29	Completed
Evaluation of Ceftazidime-avibactam Plus Aztreonam in Patients Infected by MBL-producing Enterobacterales and CRISPR/Cas9-based Strategy for Curing Drug-resistant Genes [NCT05850871]		427 participants (Anticipated)	Interventional	2023-01-06	Recruiting
A Phase 2, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Efficacy and Safety of Intravenous Coadministered Ceftaroline Fosamil and NXL104 Versus Intravenous Doripenem in Adult Subjects With Complicated Urinary Tract Infection [NCT01281462]	Phase 2	217 participants (Actual)	Interventional	2010-12-31	Completed
Comparing Oral Versus Parenteral Antimicrobial Therapy (COPAT) Trial [NCT05977868]	Phase 4	135 participants (Anticipated)	Interventional	2023-08-04	Enrolling by invitation
A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Thera [NCT01595438]	Phase 3	598 participants (Actual)	Interventional	2012-10-31	Completed
AN OPEN-LABEL, RANDOMIZED, MULTI-CENTER, ACTIVE-CONTROLLED STUDY TO ESTIMATE THE EFFICACY AND SAFETY OF CEFTAZIDIME-AVIBACTAM (CAZ-AVI) VERSUS BEST AVAILABLE TREATMENT (BAT) IN THE TREATMENT OF INFECTIONS DUE TO CARBAPENEM-RESISTANT GRAM-NEGATIVE PATHOGEN [NCT04882085]	Phase 4	59 participants (Actual)	Interventional	2021-08-26	Completed
A Phase 1, Open-Label Study in Healthy Adults to Evaluate the Safety and Pharmacokinetics of AVYCAZ(R) in Combination With Aztreonam (COMBINE) [NCT03978091]	Phase 1/Phase 2	48 participants (Actual)	Interventional	2019-07-09	Completed
Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of Injectable TQD3606 in a Single Center, Randomized, Double-blind, Placebo-controlled, Single, Multiple Dosing in Healthy Subjects, and to Explore Urinary Ex [NCT05340530]	Phase 1	56 participants (Anticipated)	Interventional	2022-04-30	Not yet recruiting
Impact of Ceftazidime / Avibactam Treatment vs Better Available Therapy on Mortality of Patients With Infections Caused by Carbapenem-resistant Enterobacteria [NCT04167228]		348 participants (Actual)	Observational	2019-10-01	Completed
Dose Optimization by PK/PD of Antibiotics to Improve Clinical Outcome of CRKP Bloodstream Infections in Critically Ill Patients and in Vitro Study of Monotherapy, Combination Therapy and Molecular Biology of Drug Resistance at Phramongkutklao Hospital: Pr [NCT05862402]	Phase 4	76 participants (Anticipated)	Interventional	2023-05-07	Recruiting
Prospective, Multicenter, Investigator-blinded, Randomized, Comparative Study Estimate Safety, Tolerability, Efficacy of NXL104/Ceftazidime vs. Comparator Followed Appropriate Oral Therapy Treatment Complicated UTI Hosp Adults [NCT00690378]	Phase 2	137 participants (Actual)	Interventional	2008-11-30	Completed
A Phase I Open-Label, 2-Part, 3-Cohort, Single-Centre Study to Assess the Concentration of Avibactam and Ceftazidime in Epithelial Lining Fluid (ELF) and Plasma Using at Least Two Different Dosing Regimens in Healthy Volunteers [NCT01395420]	Phase 1	45 participants (Actual)	Interventional	2011-08-31	Completed
A Prospective, Multicenter, Double-blind, Randomized, Comparative Study to Estimate the Safety, Tolerability and Efficacy of NXL104/Ceftazidime Plus Metronidazole vs. Meropenem in the Treatment of Complicated Intra-abdominal Infections in Hospitalized Adu [NCT00752219]	Phase 2	204 participants (Actual)	Interventional	2009-03-31	Completed
Clinical Study on Monitoring the Plasma Concentration of Ceftazidime-Avibactam in Critically Ill Patients [NCT05413343]		30 participants (Anticipated)	Observational [Patient Registry]	2022-01-01	Recruiting
A Phase I, 2-Part, Open-Label, Pharmacokinetic and Drug-Drug Interaction Study of CAZ104 (Avibactam and Ceftazidime in Healthy Subjects) [NCT01430910]	Phase 1	43 participants (Actual)	Interventional	2011-09-30	Completed
Real-World Study of Ceftazidime-Avibactam to Characterize the Usage in Clinical Practice [NCT05487586]		450 participants (Anticipated)	Observational	2022-10-20	Recruiting
A PHASE 1, OPEN-LABEL, SINGLE-DOSE STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF CEFTAZIDIME-AVIBACTAM (CAZ-AVI) IN CHILDREN FROM 3 MONTHS TO LESS THAN 18 YEARS OF AGE WHO ARE HOSPITALIZED AND RECEIVING SYSTEMIC ANTIBIOTIC THERAPY FOR S [NCT04040621]	Phase 1	4 participants (Actual)	Interventional	2020-06-15	Terminated(stopped due to Following regulatory consultation, the Sponsor has decided to terminate the study and analyze the current dataset. The decision to terminate was solely based on a business decision, not due to safety concerns.)
A PROSPECTIVE, RANDOMIZED,OPEN-LABEL, COMPARATIVE STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF AZTREONAM- AVIBACTAM (ATM-AVI) AND BEST AVAILABLE THERAPY FOR THE TREATMENT OF SERIOUS INFECTIONS DUE TO MULTI-DRUG RESISTANT GRAM- NEGATIVE BACTERI [NCT03580044]	Phase 3	15 participants (Actual)	Interventional	2020-12-25	Terminated(stopped due to Recruitment of patients with serious infections caused by gram-negative bacteria producing MBL has been challenging. Date study terminated: 16-Dec-2022.)
Pharmacokinetics of Ceftazidime-avibactam Among Critically-ill Patients Receiving Continuous Venovenous Hemodiafiltration [NCT04358991]		20 participants (Actual)	Observational	2017-01-01	Completed
AN OPEN-LABEL, PARALLEL-GROUP, PHARMACOKINETIC STUDY OF MULTIPLE INTRAVENOUS DOSES OF AZTREONAM AND AVIBACTAM IN SUBJECTS WITH SEVERE RENAL IMPAIRMENT AND NORMAL RENAL FUNCTION [NCT04486625]	Phase 1	11 participants (Actual)	Interventional	2020-08-10	Completed
A SINGLE ARM, OPEN-LABEL, MULTI-CENTER, INTERVENTIONAL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEFTAZIDIME-AVIBACTAM (CAZ-AVI) IN CHINESE ADULTS WITH HAP (INCLUDING VAP) [NCT04774094]	Phase 4	235 participants (Actual)	Interventional	2021-05-21	Completed
A Phase 1, Multicenter, Open-label, Single-dose Study to Assess the Pharmacokinetics of Ceftaroline Fosamil/Avibactam in Adults With Augmented Renal Clearance [NCT01624246]	Phase 1	12 participants (Actual)	Interventional	2012-05-31	Completed
Nosocomial Infections in Patients With Acute Respiratory Distress Syndrome Treated With Extracorporeal Membrane Oxygenation [NCT05566665]		200 participants (Anticipated)	Observational	2023-01-01	Recruiting
A PHASE 2A MULTICENTER, OBSERVER-BLINDED, RANDOMIZED 2 ARM STUDY TO INVESTIGATE PHARMACOKINETICS, SAFETY, TOLERABILITY AND EFFICACY OF INTRAVENOUS AZTREONAM-AVIBACTAM ± METRONIDAZOLE COMPARED TO BEST AVAILABLE THERAPY (BAT) IN PEDIATRIC PARTICIPANTS 9 MON [NCT05639647]	Phase 2	48 participants (Anticipated)	Interventional	2023-04-18	Recruiting
An Open Label Single-Dose Study in Healthy Male Subjects Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]NXL104 [NCT01448395]	Phase 1	6 participants (Actual)	Interventional	2011-10-31	Completed
A Study of Avycaz (Ceftazidime/Avibactam) Pharmacokinetics/Pharmacodynamics (PK/PD) in Critically Ill Patients [NCT02822950]	Phase 1	10 participants (Actual)	Interventional	2017-01-31	Completed
Steady-state Pharmacokinetics of Ceftazidime/Avibactam in CF [NCT02504827]	Phase 4	12 participants (Actual)	Interventional	2015-09-30	Completed
A Single Blind, Randomised, Multi-centre, Active Controlled, Trial To Evaluate Safety, Tolerability, Pharmacokinetics And Efficacy Of Ceftazidime And Avibactam When Given In Combination With Metronidazole, Compared With Meropenem, In Children From 3 Month [NCT02475733]	Phase 2	83 participants (Actual)	Interventional	2015-08-01	Completed
A Single Blind, Randomised, Multi-centre, Active Controlled, Trial To Evaluate Safety, Tolerability, Pharmacokinetics And Efficacy Of Ceftazidime And Avibactam Compared With Cefepime In Children From 3 Months To Less Than 18 Years Of Age With Complicated [NCT02497781]	Phase 2	97 participants (Actual)	Interventional	2015-09-24	Completed
Study on Tolerance, Pharmacokinetics and Drug Interaction of YK-1169 in Healthy Volunteers [NCT05588531]	Phase 1	66 participants (Actual)	Interventional	2021-12-20	Completed
A PHASE I, SINGLE CENTER, OPEN-LABEL STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF AZTREONAM-AVIBACTAM ADMINISTERED AS SINGLE AND REPEATED INTRAVENOUS DOSES IN HEALTHY CHINESE PARTICIPANTS [NCT04973826]	Phase 1	12 participants (Actual)	Interventional	2021-08-20	Completed
A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdo [NCT01726023]	Phase 3	486 participants (Actual)	Interventional	2013-01-31	Completed
A Phase I, Randomised, Double-blind, 3-Part Study in Healthy Young and Elderly Subjects to Assess the Safety and Tolerability, and Investigate the Pharmacokinetics of Aztreonam and Avibactam Given Alone and in Combination (ATM-AVI) [NCT01689207]	Phase 1	222 participants (Actual)	Interventional	2012-09-30	Completed
Comparative Study Between Usage of Meropenem/Gentamicin Versus Ceftazidime/Avibactam in the Treatment of ARDS Induced by Both Lung Trauma and VAP [NCT04402359]		200 participants (Actual)	Observational [Patient Registry]	2018-07-05	Completed
Ceftazidime-Avibactam Versus Colistin in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections (AVI-ICU): A Non-Inferiority Randomized Clinical Trial [NCT05258851]	Phase 3	168 participants (Anticipated)	Interventional	2022-06-01	Recruiting
A PHASE 2A, 2-PART, OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, SINGLE AND MULTIPLE DOSE TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF CEFTAZIDIME AND AVIBACTAM IN NEONATES AND INFANTS FROM BIRTH TO LESS THAN 3 MONTHS OF AGE WITH SUSPECTED O [NCT04126031]	Phase 2	48 participants (Actual)	Interventional	2020-01-14	Terminated(stopped due to Following regulatory consultation, the Sponsor has decided to terminate the study and analyze the current dataset. The decision to terminate was solely based on a business decision, not due to safety concerns.)
: Pharmacokinetics of Ceftazidime-Avibactam in Critically Ill Patients With Renal Failure Requiring Continuous Venovenous Hemodiafiltration [NCT03243864]		10 participants (Anticipated)	Observational	2017-03-13	Recruiting
An Open-Label, Randomized, Multicenter, Phase III Study of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant Gram Negative Pathogens [NCT01644643]	Phase 3	345 participants (Actual)	Interventional	2013-01-31	Completed
A Phase III, Randomized, Multicentre, Double-blind, Double-dummy, Parallel-group Comparative Study to Determine the Efficacy, Safety And Tolerability of Ceftazidime-Avibactam Versus Meropenem in the Treatment of Nosocomial Pneumonia Including Ventilator-A [NCT01808092]	Phase 3	969 participants (Actual)	Interventional	2013-04-30	Completed
A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Thera [NCT01599806]	Phase 3	641 participants (Actual)	Interventional	2012-10-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00690378 (20) [back to overview]	Microbiological Outcome for the Urine Pathogen P. Aeruginosa in ME Patients at the End of IV Therapy Visit
NCT00690378 (20) [back to overview]	Number of Participants With Microbiological Outcome at the Test of Cure (TOC) Visit
NCT00690378 (20) [back to overview]	Microbiological Outcome for the Urine Pathogen E. Coli in ME Patients at the End of IV Therapy Visit
NCT00690378 (20) [back to overview]	Clinical Outcome in CE Patients at the Late Follow-up (LFU) Visit
NCT00690378 (20) [back to overview]	Clinical Outcome in CE Patients at the TOC Visit
NCT00690378 (20) [back to overview]	Clinical Outcome in Clinically Evaluable (CE) Patients at the End of Intravenous (IV) Therapy Visit
NCT00690378 (20) [back to overview]	Microbiological Outcome for the Urine Pathogen C. Koseri in ME Patients at the End of IV Therapy Visit
NCT00690378 (20) [back to overview]	Microbiological Outcome for the Urine Pathogen C. Koseri in ME Patients at the LFU Visit
NCT00690378 (20) [back to overview]	Microbiological Outcome for the Urine Pathogen C. Koseri in ME Patients at the TOC Visit
NCT00690378 (20) [back to overview]	Microbiological Outcome for the Urine Pathogen E. Cloacae in ME Patients at the End of IV Therapy Visit
NCT00690378 (20) [back to overview]	Microbiological Outcome for the Urine Pathogen E. Cloacae in ME Patients at the TOC Visit
NCT00690378 (20) [back to overview]	Microbiological Outcome for the Urine Pathogen E. Coli in ME Patients at the LFU Visit
NCT00690378 (20) [back to overview]	Microbiological Outcome for the Urine Pathogen E. Coli in ME Patients at the TOC Visit
NCT00690378 (20) [back to overview]	Microbiological Outcome for the Urine Pathogen P. Aeruginosa in ME Patients at the LFU Visit
NCT00690378 (20) [back to overview]	Microbiological Outcome for the Urine Pathogen P. Aeruginosa in ME Patients at the TOC Visit
NCT00690378 (20) [back to overview]	Microbiological Outcome for the Urine Pathogen P. Mirabilis in ME Patients at the End of IV Therapy Visit
NCT00690378 (20) [back to overview]	Microbiological Outcome for the Urine Pathogen P. Mirabilis in ME Patients at the LFU Visit
NCT00690378 (20) [back to overview]	Microbiological Outcome for the Urine Pathogen P. Mirabilis in ME Patients at the TOC Visit
NCT00690378 (20) [back to overview]	Microbiological Outcome in ME Patients at the End of IV Therapy Visit
NCT00690378 (20) [back to overview]	Microbiological Outcome in ME Patients at the LFU Visit
NCT00752219 (10) [back to overview]	Number of Participants With Clinical Response at the End of Intravenous (IV) Therapy
NCT00752219 (10) [back to overview]	Number of Participants With Clinical Response at the Late Follow-up Visit
NCT00752219 (10) [back to overview]	Number of Participants With Clinical Response at the Test of Cure (TOC) Visit
NCT00752219 (10) [back to overview]	Number of Participants With Clinical Response in CE Participants at the End of IV Therapy
NCT00752219 (10) [back to overview]	Number of Participants With Clinical Response in CE Participants at the Late Follow-up Visit
NCT00752219 (10) [back to overview]	Number of Participants With Clinical Response in Clinically Evaluable (CE) Participants at the Test of Cure Visit
NCT00752219 (10) [back to overview]	Number of Participants With Microbiological Response at the End of IV Therapy
NCT00752219 (10) [back to overview]	Number of Participants With Microbiological Response at the Test of Cure Visit
NCT00752219 (10) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT00752219 (10) [back to overview]	Number of Participants With Microbiological Response at the Late Follow-up Visit
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at LFU for Baseline Pathogen (ME at LFU Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at LFU for Baseline Pathogen (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at LFU for Blood Only (Extended ME at LFU Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at LFU for Blood Only (ME at LFU Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at LFU for Blood Only (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (Extended ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (Extended ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at TOC for Baseline Pathogen (Extended ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at TOC for Baseline Pathogen (ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at TOC for Baseline Pathogen (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at TOC for Blood Only (Extended ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at TOC for Blood Only (ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at LFU (CE at LFU Analysis Set)
NCT01595438 (63) [back to overview]	Per-patient Microbiological Response at EOT (IV) (Extended ME at EOT (IV) Analysis Set)
NCT01595438 (63) [back to overview]	Per-patient Microbiological Response at EOT (IV) (ME at EOT (IV) Analysis Set)
NCT01595438 (63) [back to overview]	Per-patient Microbiological Response at EOT (IV) (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Per-patient Microbiological Response at LFU (Extended ME at LFU Analysis Set)
NCT01595438 (63) [back to overview]	Per-patient Microbiological Response at LFU (ME at LFU Analysis Set)
NCT01595438 (63) [back to overview]	Per-patient Microbiological Response at LFU (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Per-patient Microbiological Response at TOC (Extended ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Per-patient Microbiological Response at TOC (ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Per-patient Microbiological Response at TOC (mMITT Analysis Set): Non-inferiority Hypothesis Test
NCT01595438 (63) [back to overview]	Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (Extended ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Plasma Concentrations for Avibactam Between 30 to 90 Minutes After Dose(PK Analysis Set)
NCT01595438 (63) [back to overview]	Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Time to First Defervescence While on IV Study Therapy (CE at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Time to First Defervescence While on IV Study Therapy (Extended ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Time to First Defervescence While on IV Study Therapy (ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Time to First Defervescence While on IV Study Therapy (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Plasma Concentrations for Avibactam Between 300 to 360 Minutes After Dose(PK Analysis Set)
NCT01595438 (63) [back to overview]	Plasma Concentrations for Avibactam Within 15 Minutes Before/After Dose (PK Analysis Set)
NCT01595438 (63) [back to overview]	Plasma Concentrations for Ceftazidime Between 30 to 90 Minutes After Dose(PK Analysis Set)
NCT01595438 (63) [back to overview]	Plasma Concentrations for Ceftazidime Between 300 to 360 Minutes After Dose(PK Analysis Set)
NCT01595438 (63) [back to overview]	Plasma Concentrations for Ceftazidime Within 15 Minutes Before/After Dose (PK Analysis Set)
NCT01595438 (63) [back to overview]	Combined Patient-reported Symptomatic and Microbiological Response at TOC (mMITT Analysis Set): Non-inferiority Hypothesis Test
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at EOT (IV) (CE at EOT (IV) Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at EOT (IV) (Extended ME at EOT (IV) Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at EOT (IV) (ME at EOT (IV) Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at EOT (IV) (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at LFU (Extended ME at LFU Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at LFU (ME at LFU Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at LFU (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at TOC (CE at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at TOC (Extended ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at TOC (ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at TOC (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (Extended ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at TOC for Blood Only (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (ME at TOC Analysis Set)
NCT01595438 (63) [back to overview]	Patient-reported Symptomatic Response at Day 5 (mMITT Analysis Set): Non-inferiority Hypothesis Test
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (Extended ME at EOT (IV) Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (ME at EOT (IV) Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at EOT (IV) for Blood Only (Extended ME at EOT (IV) Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at EOT (IV) for Blood Only (ME at EOT (IV) Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at EOT (IV) for Blood Only (mMITT Analysis Set)
NCT01595438 (63) [back to overview]	Per-pathogen Microbiological Response at LFU for Baseline Pathogen (Extended ME at LFU Analysis Set)
NCT01599806 (63) [back to overview]	Per-patient Microbiological Response at TOC (Extended ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Per-patient Microbiological Response at TOC (ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Per-patient Microbiological Response at TOC (mMITT Analysis Set): Non-inferiority Hypothesis Test
NCT01599806 (63) [back to overview]	Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (Extended ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Per-patient Microbiological Response at TOC in Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Time to First Defervescence While on IV Study Therapy (CE at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Time to First Defervescence While on IV Study Therapy (Extended ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Time to First Defervescence While on IV Study Therapy (ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Time to First Defervescence While on IV Study Therapy (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Plasma Concentrations for Ceftazidime Within 15 Minutes Before/After Dose (PK Analysis Set)
NCT01599806 (63) [back to overview]	Plasma Concentrations for Avibactam Between 30 to 90 Minutes After Dose(PK Analysis Set)
NCT01599806 (63) [back to overview]	Plasma Concentrations for Avibactam Between 300 to 360 Minutes After Dose(PK Analysis Set)
NCT01599806 (63) [back to overview]	Plasma Concentrations for Avibactam Within 15 Minutes Before/After Dose (PK Analysis Set)
NCT01599806 (63) [back to overview]	Plasma Concentrations for Ceftazidime Between 30 to 90 Minutes After Dose(PK Analysis Set)
NCT01599806 (63) [back to overview]	Plasma Concentrations for Ceftazidime Between 300 to 360 Minutes After Dose(PK Analysis Set)
NCT01599806 (63) [back to overview]	Combined Patient-reported Symptomatic and Microbiological Response at TOC (mMITT Analysis Set): Non-inferiority Hypothesis Test
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at EOT (IV) (CE at EOT (IV) Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at EOT (IV) (Extended ME at EOT (IV) Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at EOT (IV) (ME at EOT (IV) Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at EOT (IV) (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at LFU (CE at LFU Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at LFU (Extended ME at LFU Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at LFU (ME at LFU Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at LFU (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at TOC (CE at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at TOC (Extended ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at TOC (ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at TOC (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (Extended ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Investigator Determined Clinical Response at TOC for Patients Infected by Ceftazidime-resistant Gram-negative Pathogen (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Patient-reported Symptomatic Response at Day 5 (mMITT Analysis Set): Non-inferiority Hypothesis Test
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (Extended ME at EOT (IV) Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (ME at EOT (IV) Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at EOT (IV) for Baseline Pathogen (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at EOT (IV) for Blood Only (Extended ME at EOT (IV) Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at EOT (IV) for Blood Only (ME at EOT (IV) Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at EOT (IV) for Blood Only (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at LFU for Baseline Pathogen (Extended ME at LFU Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at LFU for Baseline Pathogen (ME at LFU Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at LFU for Baseline Pathogen (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at LFU for Blood Only (Extended ME at LFU Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at LFU for Blood Only (ME at LFU Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at LFU for Blood Only (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (Extended ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (Extended ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at TOC for Baseline Pathogen (Extended ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at TOC for Baseline Pathogen (ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at TOC for Baseline Pathogen (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at TOC for Blood Only (Extended ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at TOC for Blood Only (ME at TOC Analysis Set)
NCT01599806 (63) [back to overview]	Per-pathogen Microbiological Response at TOC for Blood Only (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Per-patient Microbiological Response at EOT (IV) (Extended ME at EOT (IV) Analysis Set)
NCT01599806 (63) [back to overview]	Per-patient Microbiological Response at EOT (IV) (ME at EOT (IV) Analysis Set)
NCT01599806 (63) [back to overview]	Per-patient Microbiological Response at EOT (IV) (mMITT Analysis Set)
NCT01599806 (63) [back to overview]	Per-patient Microbiological Response at LFU (Extended ME at LFU Analysis Set)
NCT01599806 (63) [back to overview]	Per-patient Microbiological Response at LFU (ME at LFU Analysis Set)
NCT01599806 (63) [back to overview]	Per-patient Microbiological Response at LFU (mMITT Analysis Set)
NCT01644643 (38) [back to overview]	Per-patient Microbiological Response at EOT in EME at EOT Analysis Set
NCT01644643 (38) [back to overview]	Clinical Response at Test of Cure (TOC) in Microbiological Modified Intent-to-treat (mMITT) Analysis Set
NCT01644643 (38) [back to overview]	Clinical Response at FU2 in EME at FU2 Analysis Set
NCT01644643 (38) [back to overview]	Clinical Response at FU1 in EME at FU1 Analysis Set.
NCT01644643 (38) [back to overview]	Clinical Response at Follow-up 2 (FU2) in mMITT Analysis Set
NCT01644643 (38) [back to overview]	Clinical Cure at TOC by Baseline Gram-negative Pathogen in mMITT Analysis Set
NCT01644643 (38) [back to overview]	Clinical Response at Follow-up 1 (FU1) in mMITT Analysis Set
NCT01644643 (38) [back to overview]	Clinical Response at EOT in Extended Microbiologically Evaluable (EME) at EOT Analysis Set.
NCT01644643 (38) [back to overview]	Clinical Response at End of Treatment (EOT) in mMITT Analysis Set.
NCT01644643 (38) [back to overview]	Clinical Cure at TOC by Previously Failed Treatment Class in mMITT Analysis Set
NCT01644643 (38) [back to overview]	Plasma Concentrations for Ceftazidime and Avibactam - cIAI in PK Analysis Set
NCT01644643 (38) [back to overview]	The 28 Days All Cause Mortality Rate in EME at TOC Analysis Set
NCT01644643 (38) [back to overview]	The Reason for Treatment Change/Discontinuation in mMITT Analysis Set
NCT01644643 (38) [back to overview]	Per-patient Microbiological Response at TOC in mMITT Analysis Set
NCT01644643 (38) [back to overview]	Per-patient Microbiological Response at TOC in EME at TOC Analysis Set
NCT01644643 (38) [back to overview]	Per-patient Microbiological Response at FU2 in mMITT Analysis Set
NCT01644643 (38) [back to overview]	Per-patient Microbiological Response at FU2 in EME at FU2 Analysis Set
NCT01644643 (38) [back to overview]	Per-patient Microbiological Response at FU1 in mMITT Analysis Set
NCT01644643 (38) [back to overview]	Per-patient Microbiological Response at FU1 in EME at FU1 Analysis Set
NCT01644643 (38) [back to overview]	Per-patient Microbiological Response at EOT in mMITT Analysis Set
NCT01644643 (38) [back to overview]	Clinical Cure at TOC by Previously Failed Treatment Class in EME at TOC Analysis Set
NCT01644643 (38) [back to overview]	Per-pathogen Microbiological Response of Gram-negative Pathogen at TOC in mMITT Analysis Set
NCT01644643 (38) [back to overview]	Per-pathogen Microbiological Response of Gram-negative Pathogen at TOC in EME at TOC Analysis Set
NCT01644643 (38) [back to overview]	Per-pathogen Microbiological Response of Gram-negative Pathogen at TOC by CAZ-AVI MIC in mMITT Analysis Set
NCT01644643 (38) [back to overview]	Per-pathogen Microbiological Response of Gram-negative Pathogen at TOC by CAZ-AVI MIC in EME at TOC Analysis Set
NCT01644643 (38) [back to overview]	Per-pathogen Microbiological Response of Gram-negative Pathogen at FU2 in mMITT Analysis Set
NCT01644643 (38) [back to overview]	Per-pathogen Microbiological Response of Gram-negative Pathogen at FU2 in EME at FU2 Analysis Set
NCT01644643 (38) [back to overview]	The 28 Days All Cause Mortality Rate in mMITT Analysis Set
NCT01644643 (38) [back to overview]	Per-pathogen Microbiological Response of Gram-negative Pathogen at FU1 in mMITT Analysis Set
NCT01644643 (38) [back to overview]	Per-pathogen Microbiological Response of Gram-negative Pathogen at FU1 in EME at FU1 Analysis Set
NCT01644643 (38) [back to overview]	Per-pathogen Microbiological Response of Gram-negative Pathogen at EOT in mMITT Analysis Set
NCT01644643 (38) [back to overview]	Per-pathogen Microbiological Response of Gram-negative Pathogen at EOT in EME at EOT Analysis Set
NCT01644643 (38) [back to overview]	Clinical Response at TOC in EME at TOC Analysis Set.
NCT01644643 (38) [back to overview]	Clinical Cure at TOC by Baseline Gram-negative Pathogen in EME at TOC Analysis Set
NCT01644643 (38) [back to overview]	Clinical Cure at FU2 by Previously Failed Treatment Class in EME at FU2 Analysis Set
NCT01644643 (38) [back to overview]	Clinical Cure at FU1 by Previously Failed Treatment Class in EME at FU1 Analysis Set
NCT01644643 (38) [back to overview]	Clinical Cure at EOT by Previously Failed Treatment Class in EME at EOT Analysis Set
NCT01644643 (38) [back to overview]	Plasma Concentrations for Ceftazidime and Avibactam - cUTI in PK Analysis Set
NCT01689207 (7) [back to overview]	Safety Profile - Number of Subjects With at Least 1 AE
NCT01689207 (7) [back to overview]	PK- Plasma Pharmacokinetic Parameter AUC (ug*h/mL) for Aztreonam (ATM) and Avibactam (AVI) Alone and in Combination (ATM-AVI) in Parts A, B and C
NCT01689207 (7) [back to overview]	PK- Plasma Pharmacokinetic Parameter Cmax for Aztreonam (ATM) and Avibactam (AVI) Alone and in Combination (ATM-AVI) in Parts A, B and C
NCT01689207 (7) [back to overview]	PK- Plasma Pharmacokinetic Parameter t1/2(h) for Aztreonam (ATM) and Avibactam (AVI) Alone and in Combination (ATM-AVI) in Parts A, B and C
NCT01689207 (7) [back to overview]	PK- Plasma Pharmacokinetic Parameter Tmax for Aztreonam (ATM) and Avibactam (AVI) Alone and in Combination (ATM-AVI) on Day 1 in Parts A, B and C
NCT01689207 (7) [back to overview]	PK- Plasma Pharmacokinetic Parameter Vss for Aztreonam (ATM) and Avibactam (AVI) Alone and in Combination (ATM-AVI) in Parts A, B and C
NCT01689207 (7) [back to overview]	PK- Plasma Pharmacokinetic Parameters CL and CLr for Aztreonam (ATM) and Avibactam (AVI) Alone and in Combination (ATM-AVI) in Parts A, B and C
NCT01726023 (41) [back to overview]	The Proportion of Favorable Per-pathogen Microbiological Response at the End of Treatment (EOT) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	Safety and Tolerability:ECG , QTcB and QTcF Intervals
NCT01726023 (41) [back to overview]	Safety and Tolerability: Clinical Laboratory Evaluation Hematology.
NCT01726023 (41) [back to overview]	Safety and Tolerability: Clinical Laboratory Evaluation Clinical Chemistry.
NCT01726023 (41) [back to overview]	Safety and Tolerability by Incidence: Extent of Exposure.
NCT01726023 (41) [back to overview]	The Proportion of Patients With Clinical Cure at the End of Treatment (EOT) Visit in the Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With Clinical Cure at the Late Follow up (LFU) Visit in the Clinically Evaluable (CE) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With Clinical Cure at the Late Follow up (LFU) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With Clinical Cure at the Late Follow up (LFU) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With Clinical Cure at the Late Follow up (LFU) Visit in the Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Clinically Evaluable (CE) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	Safety and Tolerability by Incidence and Severity of Adverse Events and Serious Adverse Events and Mortality.
NCT01726023 (41) [back to overview]	The Time to First Defervescence in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set for Patients Who Have Fever at Study Entry.
NCT01726023 (41) [back to overview]	The Time to First Defervescence in the Clinically Evaluable (CE) Analysis Set for Patients Who Have Fever at Study Entry.
NCT01726023 (41) [back to overview]	Plasma Concentrations for Ceftazidime and Avibactam
NCT01726023 (41) [back to overview]	The Proportion of Favorable Per-pathogen Microbiological Response at the End of Treatment (EOT) Visit in the Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Favorable Per-pathogen Microbiological Response at the End of Treatment (EOT) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With Clinical Cure at the End of Treatment (EOT) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With Clinical Cure at the End of Treatment (EOT) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With Clinical Cure at the End of Treatment (EOT) Visit in the Clinically Evaluable (CE) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Test of Cure (TOC) Visit in the Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Late Follow up (LFU) Visit in the Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Late Follow up (LFU) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Late Follow up (LFU) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With a Favorable Per-patient Microbiological Response at the End of Treatment (EOT) Visit in the Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With a Favorable Per-patient Microbiological Response at the End of Treatment (EOT) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With a Favorable Per-patient Microbiological Response at the End of Treatment (EOT) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With a Favorable Per Patient Microbiological Response at the Test of Cure (TOC) Visit for Patients Infected With Ceftazidime Resistant Pathogens in the Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With a Favorable Per Patient Microbiological Response at the Test of Cure (TOC) Visit for Patients Infected With Ceftazidime Resistant Pathogens in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With a Favorable Per-patient Microbiological Response at the Test of Cure (TOC) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Patients With a Favorable Per Patient Microbiological Response at the Test of Cure (TOC) Visit for Patients Infected With Ceftazidime Resistant Pathogens in the Extended Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Favorable Per-pathogen Microbiological Response in the Microbiological Response at the Test of Cure (TOC) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Favorable Per-pathogen Microbiological Response in the Microbiological Response at the Late Follow up (LFU) Visit in the Microbiological Modified Intent-to-treat (mMITT) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Favorable Per-pathogen Microbiological Response at the Test of Cure (TOC) Visit in the Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Favorable Per-pathogen Microbiological Response at the Test of Cure (TOC) Visit in the Extended Microbiologically Evaluable(ME) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Favorable Per-pathogen Microbiological Response at the Late Follow up (LFU) Visit in the Microbiologically Evaluable (ME) Analysis Set.
NCT01726023 (41) [back to overview]	The Proportion of Favorable Per-pathogen Microbiological Response at the Late Follow up (LFU) Visit in the Extended Microbiologically Evaluable (ME) Analysis Set.
NCT01808092 (49) [back to overview]	The Number of Patients With Clinical Cure at Test-of-cure (TOC) Visit in the Clinically Modified Intent-to-treat Analysis Set (Co-primary Analyses)
NCT01808092 (49) [back to overview]	The Number of Patients With Clinical Cure at Test-of-cure (TOC) Visit in the Extended Microbiologically Evaluable Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With Clinical Cure at Test-of-cure (TOC) Visit in the Microbiologically Evaluable Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With Clinical Cure at Test-of-cure (TOC) Visit in the Microbiologically Modified Intent-to-treat Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With Clinical Cure in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Clinically Modified Intent-to-treat Analysis Set at End of Treatment Visit
NCT01808092 (49) [back to overview]	The Number of Patients With Clinical Cure in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Microbiologically Evaluable at End of Treatment Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With Clinical Cure in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Clinically Evaluable at Test-of-cure Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With Clinical Cure in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Clinically Modified Intent-to-treat Analysis Set at Test-of-cure Visit
NCT01808092 (49) [back to overview]	The Number of Patients With Clinical Cure in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Microbiologically Evaluable at Test-of-cure Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With Death Due to Any Cause (All-cause Mortality) at Test-of-cure (TOC) Visit in Clinically Modified Intent-to-treat Analysis Set at Test-of-cure Visit
NCT01808092 (49) [back to overview]	The Number of Patients With Death Due to Any Cause (All-cause Mortality) at Test-of-cure (TOC) Visit in Microbiologically Modified Intent-to-treat Analysis Set at Test-of-cure Visit
NCT01808092 (49) [back to overview]	The Number of Patients With Death Due to Any Cause (All-cause Mortality) at Test-of-cure (TOC) Visit in the Clinically Evaluable at Test-of-cure Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With Death Due to Any Cause (All-cause Mortality) in Clinically Modified Intent-to-treat Analysis Set at Day 28
NCT01808092 (49) [back to overview]	The Number of Patients With Death Due to Any Cause (All-cause Mortality) in Microbiologically Modified Intent-to-treat Analysis Set at Day 28
NCT01808092 (49) [back to overview]	The Number of Patients With Death Due to Any Cause (All-cause Mortality) in the Clinically Evaluable at Test-of-cure Analysis Set at Day 28
NCT01808092 (49) [back to overview]	The Number of Patients With Clinical Cure in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Clinically Evaluable at End of Treatment Analysis Set
NCT01808092 (49) [back to overview]	Number of Patients With a Favorable Per-patient Microbiologic Response in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Extended Microbiologically Evaluable at End of Treatment Analysis Set
NCT01808092 (49) [back to overview]	Number of Patients With a Favorable Per-patient Microbiologic Response in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Microbiologically Evaluable at End of Treatment Analysis Set
NCT01808092 (49) [back to overview]	Number of Patients With a Favorable Per-patient Microbiologic Response in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Microbiologically Modified Intent-to-treat Analysis Set at End of Treatment Visit
NCT01808092 (49) [back to overview]	Number of Patients With a Favorable Per-patient Microbiologic Response in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Extended Microbiologically Evaluable at Test-of-cure Analysis Set
NCT01808092 (49) [back to overview]	Number of Patients With a Favorable Per-patient Microbiologic Response in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Microbiologically Evaluable at Test-of-cure Analysis Set
NCT01808092 (49) [back to overview]	Number of Patients With a Favorable Per-patient Microbiologic Response in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Microbiologically Modified Intent-to-treat Analysis Set at Test-of-cure Visit
NCT01808092 (49) [back to overview]	The Number of Favorable Per-pathogen Microbiologic Responses at End of Treatment (EOT) Visit in Extended Microbiologically Evaluable at End of Treatment Analysis Set
NCT01808092 (49) [back to overview]	The Number of Favorable Per-pathogen Microbiologic Responses at End of Treatment (EOT) Visit in Microbiologically Evaluable at End of Treatment Analysis Set
NCT01808092 (49) [back to overview]	The Number of Favorable Per-pathogen Microbiologic Responses at End of Treatment (EOT) Visit in Microbiologically Modified Intent-to-treat Analysis Set at End of Treatment Visit
NCT01808092 (49) [back to overview]	The Number of Favorable Per-pathogen Microbiologic Responses at Test-of-cure (TOC) Visit in Extended Microbiologically Evaluable at Test-of-cure Analysis Set
NCT01808092 (49) [back to overview]	The Number of Favorable Per-pathogen Microbiologic Responses at Test-of-cure (TOC) Visit in Microbiologically Evaluable at Test-of-cure Analysis Set
NCT01808092 (49) [back to overview]	The Number of Favorable Per-pathogen Microbiologic Responses at Test-of-cure (TOC) Visit in Microbiologically Modified Intent-to-treat Analysis Set at Test-of-cure Visit
NCT01808092 (49) [back to overview]	The Number of Favorable Per-pathogen Microbiologic Responses in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Extended Microbiologically Evaluable at End of Treatment Analysis Set
NCT01808092 (49) [back to overview]	The Number of Favorable Per-pathogen Microbiologic Responses in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Microbiologically Evaluable at End of Treatment Analysis Set
NCT01808092 (49) [back to overview]	The Number of Favorable Per-pathogen Microbiologic Responses in Patients With Pathogens Resistant to Ceftazidime at End of Treatment (EOT) Visit in Microbiologically Modified Intent-to-treat Analysis Set at End of Treatment Visit
NCT01808092 (49) [back to overview]	The Number of Favorable Per-pathogen Microbiologic Responses in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Extended Microbiologically Evaluable at Test-of-cure Analysis Set
NCT01808092 (49) [back to overview]	The Number of Favorable Per-pathogen Microbiologic Responses in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Microbiologically Evaluable at Test-of-cure Analysis Set
NCT01808092 (49) [back to overview]	The Number of Favorable Per-pathogen Microbiologic Responses in Patients With Pathogens Resistant to Ceftazidime at Test-of-cure (TOC) Visit in Microbiologically Modified Intent-to-treat Analysis Set at Test-of-cure Visit
NCT01808092 (49) [back to overview]	The Number of Patients Discharged From Hospital up to Test-of-cure (TOC) Visit in Microbiologically Modified Intent-to-treat Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients Discharged From Hospital up to Test-of-cure (TOC) Visit in the Clinically Evaluable at Test-of-cure Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients Discharged From Hospital up to Test-of-cure (TOC) Visit in the Clinically Modified Intent-to-treat Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With a Favorable Per-patient Microbiologic Response at End of Treatment (EOT) Visit in Extended Microbiologically Evaluable at End of Treatment Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With a Favorable Per-patient Microbiologic Response at End of Treatment (EOT) Visit in Microbiologically Evaluable at End of Treatment Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With a Favorable Per-patient Microbiologic Response at End of Treatment (EOT) Visit in Microbiologically Modified Intent-to-treat Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With a Favorable Per-patient Microbiologic Response at Test-of-cure (TOC) Visit in Extended Microbiologically Evaluable at Test-of-cure Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With a Favorable Per-patient Microbiologic Response at Test-of-cure (TOC) Visit in Microbiologically Evaluable at Test-of-cure Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With a Favorable Per-patient Microbiologic Response at Test-of-cure (TOC) Visit in Microbiologically Modified Intent-to-treat Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With Clinical Cure at End of Treatment (EOT) Visit in Clinically Evaluable Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With Clinical Cure at End of Treatment (EOT) Visit in Clinically Modified Intent-to-treat Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With Clinical Cure at End of Treatment (EOT) Visit in Extended Microbiologically Evaluable Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With Clinical Cure at End of Treatment (EOT) Visit in Microbiologically Evaluable Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With Clinical Cure at End of Treatment (EOT) Visit in Microbiologically Modified Intent-to-treat Analysis Set
NCT01808092 (49) [back to overview]	The Number of Patients With Clinical Cure at Test-of-cure (TOC) Visit in the Clinically Evaluable at TOC Analysis Set (Co-primary Analyses)
NCT02475733 (26) [back to overview]	Percentage of Participants With Cephalosporin Class Effects and Additional Adverse Events (AEs)
NCT02475733 (26) [back to overview]	Percentage of Participants With Creatinine Clearance (CrCl) at Day 7
NCT02475733 (26) [back to overview]	Percentage of Participants With Creatinine Clearance (CrCl) at End of Intravenous Therapy (EOIV) Visit
NCT02475733 (26) [back to overview]	Percentage of Participants With Creatinine Clearance (CrCl) at Late Follow-up (LFU) Visit
NCT02475733 (26) [back to overview]	Percentage of Participants With Creatinine Clearance (CrCl) at Test of Cure (TOC) Visit
NCT02475733 (26) [back to overview]	Percentage of Participants With Electrocardiogram (ECG) Parameter QTcF: > 450, >480 and >500 Millisecond (ms)
NCT02475733 (26) [back to overview]	Percentage of Participants With Favorable Clinical Response (CR) at Test of Cure (TOC) Visit: Intent-to-treat (ITT) Analysis Population
NCT02475733 (26) [back to overview]	Percentage of Participants With Clinical Relapse at Late Follow-up (LFU) Visit: Microbiologically Evaluable (ME) Population
NCT02475733 (26) [back to overview]	Percentage of Participants With Favorable Microbiological Response: Microbiological Intent-to-treat (Micro-ITT) Population
NCT02475733 (26) [back to overview]	Percentage of Participants With Favorable Clinical Response (CR): Clinically Evaluable (CE) Analysis Population
NCT02475733 (26) [back to overview]	Percentage of Participants With Favorable Microbiological Response: Microbiologically Evaluable (ME) Population
NCT02475733 (26) [back to overview]	Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT02475733 (26) [back to overview]	Percentage of Participants With Favorable Clinical Response (CR) at End of Treatment (EOT) Visit: Intent-to-treat (ITT) Analysis Population
NCT02475733 (26) [back to overview]	Plasma Concentrations of Ceftazidime and Avibactam
NCT02475733 (26) [back to overview]	Percentage of Participants With Potentially Clinically Significant Abnormalities in Laboratory Parameters
NCT02475733 (26) [back to overview]	Percentage of Participants With Clinical Relapse at Late Follow-up (LFU) Visit: Clinically Evaluable (CE) Population
NCT02475733 (26) [back to overview]	Percentage of Participants With Emergent Infections at Test of Cure (TOC) Visit: Microbiologically Evaluable Population
NCT02475733 (26) [back to overview]	Percentage of Participants With Emergent Infections: Microbiological Intent-to-treat (Micro-ITT) Population
NCT02475733 (26) [back to overview]	Percentage of Participants With Favorable Clinical Response (CR) at End of 72 Hours Treatment: Intent-to-treat (ITT) Analysis Population
NCT02475733 (26) [back to overview]	Percentage of Participants With Favorable Clinical Response (CR) at End of Intravenous Therapy (EOIV) Visit: Intent-to-treat (ITT) Analysis Population
NCT02475733 (26) [back to overview]	Change From Baseline in Body Temperature at End of Intravenous Therapy (EOIV) Visit
NCT02475733 (26) [back to overview]	Change From Baseline in Body Weight at End of Intravenous Therapy (EOIV) Visit
NCT02475733 (26) [back to overview]	Change From Baseline in Pulse Rate at End of Intravenous Therapy (EOIV) Visit
NCT02475733 (26) [back to overview]	Change From Baseline in Respiratory Rate at End of Intravenous Therapy (EOIV) Visit
NCT02475733 (26) [back to overview]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at End of Intravenous Therapy (EOIV) Visit
NCT02475733 (26) [back to overview]	Percentage of Participants With Abnormal Physical Examination Findings at End of Intravenous Therapy (EOIV) Visit
NCT02497781 (29) [back to overview]	Change From Baseline in Body Weight at End of Intravenous Treatment (EOIV) Visit
NCT02497781 (29) [back to overview]	Change From Baseline in Body Temperature at End of Intravenous Treatment (EOIV) Visit
NCT02497781 (29) [back to overview]	Percentage of Participants With Favourable Clinical Response (CR) at TOC: Clinically Evaluable (CE) Analysis Set at TOC
NCT02497781 (29) [back to overview]	Percentage of Participants With Favourable Clinical Response (CR) at End of Treatment (EOT) Visit: Clinically Evaluable (CE) Analysis Set at EOT
NCT02497781 (29) [back to overview]	Percentage of Participants With Favourable Clinical Response (CR) at End of Intravenous Treatment (EOIV) Visit: Clinically Evaluable (CE) Analysis Set at EOIV
NCT02497781 (29) [back to overview]	Percentage of Participants With Clinical Relapse at Late Follow-up (LFU) Visit: Clinically Evaluable (CE) Analysis Set at LFU
NCT02497781 (29) [back to overview]	Change From Baseline in Pulse Rate at End of Intravenous Treatment (EOIV) Visit
NCT02497781 (29) [back to overview]	Plasma Concentrations of Ceftazidime and Avibactam
NCT02497781 (29) [back to overview]	Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT02497781 (29) [back to overview]	Percentage of Participants With Potentially Clinically Significant Abnormalities in Laboratory Parameters
NCT02497781 (29) [back to overview]	Percentage of Participants With Potentially Clinically Significant Abnormalities in Electrocardiogram (ECG) Parameters
NCT02497781 (29) [back to overview]	Percentage of Participants With Favourable Microbiological Response: Microbiologically Evaluable (ME) Analysis Population
NCT02497781 (29) [back to overview]	Percentage of Participants With Favourable Microbiological Response: Microbiological Intent-to-treat (Micro-ITT) Population
NCT02497781 (29) [back to overview]	Percentage of Participants With Favourable Combined Response: Microbiological Intent-to-treat (Micro-ITT) Population
NCT02497781 (29) [back to overview]	Percentage of Participants With Favourable Clinical Response (CR) at End of 72 Hours Treatment: Clinically Evaluable (CE) Analysis Set at 72 Hours
NCT02497781 (29) [back to overview]	Percentage of Participants With Emergent Infections: Microbiologically Evaluable (ME) Analysis Population
NCT02497781 (29) [back to overview]	Percentage of Participants With Emergent Infections: Microbiological Intent-to-treat (Micro-ITT) Population
NCT02497781 (29) [back to overview]	Percentage of Participants With Clinical Relapse at Late Follow-up (LFU) Visit: Microbiologically Evaluable (ME) Analysis Set at LFU
NCT02497781 (29) [back to overview]	Percentage of Participants With Favourable Clinical Response (CR): Microbiologically Evaluable (ME) Analysis Population
NCT02497781 (29) [back to overview]	Percentage of Participants With Favourable Clinical Response (CR): Microbiological ITT (Micro-ITT) Analysis Population
NCT02497781 (29) [back to overview]	Percentage of Participants With Favourable Clinical Response (CR): Intent-to-treat (ITT) Analysis Population
NCT02497781 (29) [back to overview]	Percentage of Participants With Creatinine Clearance (CrCl) at Test of Cure (TOC) Visit
NCT02497781 (29) [back to overview]	Percentage of Participants With Creatinine Clearance (CrCl) at End of Intravenous Treatment (EOIV) Visit
NCT02497781 (29) [back to overview]	Percentage of Participants With Creatinine Clearance (CrCl) at Day 7
NCT02497781 (29) [back to overview]	Percentage of Participants With Combined Response: Microbiologically Evaluable (ME) Analysis Population
NCT02497781 (29) [back to overview]	Percentage of Participants With Cephalosporin Class Effects and Additional Adverse Events (AEs)
NCT02497781 (29) [back to overview]	Percentage of Participants With Abnormal Physical Examination Findings at End of Intravenous Treatment (EOIV) Visit
NCT02497781 (29) [back to overview]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at End of Intravenous Treatment (EOIV) Visit
NCT02497781 (29) [back to overview]	Change From Baseline in Respiratory Rate at End of Intravenous Treatment (EOIV) Visit
NCT02504827 (2) [back to overview]	Peak Sputum Concentration
NCT02504827 (2) [back to overview]	Peak Plasma Concentration (Cmax)
NCT02822950 (5) [back to overview]	Mean (SD) Ceftazadime/Avibactam Pharmacokinetic Half Life Parameter in Intensive Care Patients
NCT02822950 (5) [back to overview]	Mean (SD) Ceftazadime/Avibactam Pharmacokinetic (PK) Maximum Serum Concentration in Intensive Care Patients
NCT02822950 (5) [back to overview]	Mean (SD) Ceftazadime/Avibactam Pharmacokinetic Clearance of Drug Parameter in Intensive Care Patients
NCT02822950 (5) [back to overview]	Mean (SD) Ceftazadime/Avibactam Pharmacokinetic Area Under Serum Curve (mg*h/L) Parameter in Intensive Care Patients
NCT02822950 (5) [back to overview]	Mean (SD) Ceftazadime/Avibactam Pharmacokinetic (PK) Volume of Distribution Parameter in Intensive Care Patients
NCT03978091 (40) [back to overview]	Accumulation Ratio for Cmax (Maximum Plasma Concentration) (RCmax)
NCT03978091 (40) [back to overview]	Area Under the Plasma Concentration-time Curve Data of Study Drug During the Dosing Interval on Day 1 [AUC(0-Tau)]
NCT03978091 (40) [back to overview]	Area Under the Plasma Concentration-time Curve Data of Study Drug During the Dosing Interval on Day 1 [AUC(0-Tau)]
NCT03978091 (40) [back to overview]	Area Under the Plasma Concentration-time Curve of Study Drug From Time of Dosing Extrapolated to Infinity [AUC(0-Inf)]
NCT03978091 (40) [back to overview]	Area Under the Plasma Concentration-time Curve of Study Drug From Time of Dosing Extrapolated to Infinity [AUC(0-Inf)]
NCT03978091 (40) [back to overview]	Area Under the Plasma Concentration-time Curve of Study Drug From Time of Dosing Extrapolated to Infinity [AUC(0-Inf)]
NCT03978091 (40) [back to overview]	Concentration of Study Drug at Steady State After Continuous Infusion (Css)
NCT03978091 (40) [back to overview]	Maximum Plasma Concentration of Study Drug After the First Dose (Cmax)
NCT03978091 (40) [back to overview]	Volume of Distribution of Study Drug at Steady-state Based on the Last Observed Concentration (Vss)
NCT03978091 (40) [back to overview]	Incidence of Treatment-emergent Adverse Events, by System Organ Class (SOC) and Maximum Severity Level
NCT03978091 (40) [back to overview]	Total Body Plasma Clearance of Study Drug (CL)
NCT03978091 (40) [back to overview]	Total Body Plasma Clearance of Study Drug (CL)
NCT03978091 (40) [back to overview]	Volume of Distribution of Study Drug at Steady-state Based on the Last Observed Concentration (Vss)
NCT03978091 (40) [back to overview]	Total Body Plasma Clearance of Study Drug (CL)
NCT03978091 (40) [back to overview]	Time to Cmax (Maximum Plasma Concentration) of Study Drug Following Multiple Daily Dosing (Tmax)
NCT03978091 (40) [back to overview]	Accumulation Ratio for AUC (Area Under the Plasma Concentration-time Curve of Study Drug) [RAUC]
NCT03978091 (40) [back to overview]	Time to Cmax (Maximum Plasma Concentration) of Study Drug Following Multiple Daily Dosing (Tmax)
NCT03978091 (40) [back to overview]	Area Under the Plasma Concentration-time Curve Data of Study Drug During the Dosing Interval on Day 1 [AUC(0-Tau)]
NCT03978091 (40) [back to overview]	Time of Cmax (Maximum Plasma Concentration) of Study Drug After the First Dose (Tmax)
NCT03978091 (40) [back to overview]	Time of Cmax (Maximum Plasma Concentration) of Study Drug After the First Dose (Tmax)
NCT03978091 (40) [back to overview]	Time of Cmax (Maximum Plasma Concentration) of Study Drug After the First Dose (Tmax)
NCT03978091 (40) [back to overview]	Renal Clearance of Study Drug (CLR)
NCT03978091 (40) [back to overview]	Renal Clearance of Study Drug (CLR)
NCT03978091 (40) [back to overview]	Renal Clearance of Study Drug (CLR)
NCT03978091 (40) [back to overview]	Number of Participants With at Least One Grade 2 (Moderate) or Higher Treatment-emergent Adverse Event
NCT03978091 (40) [back to overview]	Minimum Plasma Concentration of Study Drug Following Multiple Daily Dosing on Day 1 (Cmin)
NCT03978091 (40) [back to overview]	Minimum Plasma Concentration of Study Drug Following Multiple Daily Dosing on Day 1 (Cmin)
NCT03978091 (40) [back to overview]	Minimum Plasma Concentration of Study Drug Following Multiple Daily Dosing on Day 1 (Cmin)
NCT03978091 (40) [back to overview]	Maximum Plasma Concentration of Study Drug Following Multiple Daily Dosing (Cmax)
NCT03978091 (40) [back to overview]	Maximum Plasma Concentration of Study Drug Following Multiple Daily Dosing (Cmax)
NCT03978091 (40) [back to overview]	Maximum Plasma Concentration of Study Drug Following Multiple Daily Dosing (Cmax)
NCT03978091 (40) [back to overview]	Maximum Plasma Concentration of Study Drug After the First Dose (Cmax)
NCT03978091 (40) [back to overview]	Maximum Plasma Concentration of Study Drug After the First Dose (Cmax)
NCT03978091 (40) [back to overview]	Time to Cmax (Maximum Plasma Concentration) of Study Drug Following Multiple Daily Dosing (Tmax)
NCT03978091 (40) [back to overview]	Accumulation Ratio for AUC (Area Under the Plasma Concentration-time Curve of Study Drug) [RAUC]
NCT03978091 (40) [back to overview]	Volume of Distribution of Study Drug at Steady-state Based on the Last Observed Concentration (Vss)
NCT03978091 (40) [back to overview]	Accumulation Ratio for AUC (Area Under the Plasma Concentration-time Curve of Study Drug) [RAUC]
NCT03978091 (40) [back to overview]	Accumulation Ratio for Cmax (Maximum Plasma Concentration) (RCmax)
NCT03978091 (40) [back to overview]	Accumulation Ratio for Cmax (Maximum Plasma Concentration) (RCmax)
NCT03978091 (40) [back to overview]	Concentration of Study Drug at Steady State After Continuous Infusion (Css)
NCT04358991 (1) [back to overview]	Serum Levels of Ceftazidime and Avibactam Among Critically-ill Patients
NCT04486625 (29) [back to overview]	Time for Cmax (Tmax) of ATM
NCT04486625 (29) [back to overview]	Tmax of AVI
NCT04486625 (29) [back to overview]	Total Daily Area Under the Plasma Concentration-time Profile From Time 0 to 24 Hours at Steady-state (AUC0-24,ss) of Aztreonam (ATM)
NCT04486625 (29) [back to overview]	Vss of AVI
NCT04486625 (29) [back to overview]	Vz of AVI
NCT04486625 (29) [back to overview]	Ae0-tau of AVI
NCT04486625 (29) [back to overview]	Ae0-tau% of AVI
NCT04486625 (29) [back to overview]	Apparent Volume of Distribution (Vz) of ATM
NCT04486625 (29) [back to overview]	Apparent Volume of Distribution at Steady-state (Vss) of ATM
NCT04486625 (29) [back to overview]	Area Under the Plasma Concentration-time Profile From Time 0 to Time Tau (The Dosing Interval)(AUC0-tau) of ATM
NCT04486625 (29) [back to overview]	AUC0-24,ss of Avibactam (AVI)
NCT04486625 (29) [back to overview]	AUC0-tau of AVI
NCT04486625 (29) [back to overview]	CL of AVI
NCT04486625 (29) [back to overview]	Clearance (CL) of ATM
NCT04486625 (29) [back to overview]	CLr of AVI
NCT04486625 (29) [back to overview]	Cmax of AVI
NCT04486625 (29) [back to overview]	Ctau of AVI
NCT04486625 (29) [back to overview]	Cumulative Amount of Drug Recovered Unchanged in Urine up to Time Tau (Ae0-tau) of ATM
NCT04486625 (29) [back to overview]	Maximum Plasma Concentration (Cmax) of ATM
NCT04486625 (29) [back to overview]	Observed Plasma Concentration at the End of the Dosing Interval (Tau) (Ctau) of ATM
NCT04486625 (29) [back to overview]	Percent of Dose Recovered Unchanged in Urine up to Time Tau (Ae0-tau%) of ATM
NCT04486625 (29) [back to overview]	Renal Clearance (CLr) of ATM
NCT04486625 (29) [back to overview]	t1/2 of AVI
NCT04486625 (29) [back to overview]	Terminal Elimination Half-life (t1/2) of ATM
NCT04486625 (29) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAEs) (All-causality)
NCT04486625 (29) [back to overview]	Number of Participants With TEAEs (Treatment-related)
NCT04486625 (29) [back to overview]	Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)
NCT04486625 (29) [back to overview]	Number of Participants With Categorical Post-Baseline Vital Signs Data
NCT04486625 (29) [back to overview]	Number of Participants With Abnormal Electrocardiogram (ECG)
NCT04973826 (34) [back to overview]	Time of Observed Maximum Plasma Concentration (Tmax) on Day 1 & 4 of Aztreonam
NCT04973826 (34) [back to overview]	Accumulation Ratio for AUCτ Following Multiple Dosing (Rac) on Day 4 of Aztreonam
NCT04973826 (34) [back to overview]	Area Under the Plasma Concentration-Time Profile From Time 0 to 6 Hours (AUC6) on Day 1 of Aztreonam
NCT04973826 (34) [back to overview]	Area Under the Plasma Concentration-Time Profile From Time 0 to the Time of the End of the Dosing Interval (τ), Where τ=6 Hours (AUCtau) on Day 4 of Avibactam
NCT04973826 (34) [back to overview]	Area Under the Plasma Concentration-Time Profile From Time 0 to the Time of the End of the Dosing Interval (τ), Where τ=6 Hours (AUCtau) on Day 4 of Aztreonam
NCT04973826 (34) [back to overview]	Total Daily Area Under the Plasma Concentration-Time Profile From Time 0 to 24 Hours at Steady-State (AUC24,ss) on Day 4 of Avibactam
NCT04973826 (34) [back to overview]	Total Daily Area Under the Plasma Concentration-Time Profile From Time 0 to 24 Hours at Steady-State (AUC24,ss) on Day 4 of Aztreonam
NCT04973826 (34) [back to overview]	Accumulation Ratio for AUCτ Following Multiple Dosing (Rac) on Day 4 of Avibactam
NCT04973826 (34) [back to overview]	Apparent Volume of Distribution at Steady-State (Vss) on Day 1 & 4 of Avibactam
NCT04973826 (34) [back to overview]	Apparent Volume of Distribution at Steady-State (Vss) on Day 1 & 4 of Aztreonam
NCT04973826 (34) [back to overview]	Apparent Volume of Distribution During Terminal Phase (Vz) on Day 1 & 4 of Avibactam
NCT04973826 (34) [back to overview]	Apparent Volume of Distribution During Terminal Phase (Vz) on Day 1 & 4 of Aztreonam
NCT04973826 (34) [back to overview]	Area Under the Plasma Concentration-Time Profile From Time 0 to 24 Hours (AUC24) on Day 1 & 4 of Avibactam
NCT04973826 (34) [back to overview]	Number of Participants With Abnormal Vital Signs
NCT04973826 (34) [back to overview]	Area Under the Plasma Concentration-Time Profile From Time 0 to 24 Hours (AUC24) on Day 1 & 4 of Aztreonam
NCT04973826 (34) [back to overview]	Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) on Day 1 & 4 of Avibactam
NCT04973826 (34) [back to overview]	Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) on Day 1 & 4 of Aztreonam
NCT04973826 (34) [back to overview]	Area Under the Plasma Concentration-Time Profile From Time Zero to Time of the Last Quantifiable Concentration (AUClast) on Day 1 & 4 of Avibactam
NCT04973826 (34) [back to overview]	Area Under the Plasma Concentration-Time Profile From Time Zero to Time of the Last Quantifiable Concentration (AUClast) on Day 1 & 4 of Aztreonam
NCT04973826 (34) [back to overview]	Clearance (CL) on Day 1 & 4 of Avibactam
NCT04973826 (34) [back to overview]	Clearance (CL) on Day 1 & 4 of Aztreonam
NCT04973826 (34) [back to overview]	Maximum Observed Plasma Concentration (Cmax) on Day 1 & 4 of Avibactam
NCT04973826 (34) [back to overview]	Maximum Observed Plasma Concentration (Cmax) on Day 1 & 4 of Aztreonam
NCT04973826 (34) [back to overview]	Number of Participants With Abnormal Electrocardiograms (ECGs)
NCT04973826 (34) [back to overview]	Number of Participants With Abnormal Laboratory Assessments
NCT04973826 (34) [back to overview]	Area Under the Plasma Concentration-Time Profile From Time 0 to 6 Hours (AUC6) on Day 1 of Avibactam
NCT04973826 (34) [back to overview]	Number of Participants With an Adverse Event (AE)
NCT04973826 (34) [back to overview]	Accumulation Ratio for Cmax (Rac,Cmax) on Day 4 of Aztreonam
NCT04973826 (34) [back to overview]	Renal Clearance (CLr) on Day 1 & 4 of Avibactam
NCT04973826 (34) [back to overview]	Accumulation Ratio for Cmax (Rac,Cmax) on Day 4 of Avibactam
NCT04973826 (34) [back to overview]	Terminal Elimination Half-Life (T1/2) on Day 1 & 4 of Avibactam
NCT04973826 (34) [back to overview]	Terminal Elimination Half-Life (T1/2) on Day 1 & 4 of Aztreonam
NCT04973826 (34) [back to overview]	Time of Observed Maximum Plasma Concentration (Tmax) on Day 1 & 4 of Avibactam
NCT04973826 (34) [back to overview]	Renal Clearance (CLr) on Day 1 & 4 of Aztreonam

Microbiological Outcome for the Urine Pathogen P. Aeruginosa in ME Patients at the End of IV Therapy Visit

Eradication: a uropathogen found at entry at >10^5 CFU/mL was reduced to <10^4 CFU/mL (NCT00690378)
Timeframe: End of IV therapy (4 to 14 days)

Intervention	Participants (Number)
NXL104/CAZ	1
Imipenem Cilastatin	0

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=179, 194)	Klebsiella pneumoniae - Favorable (n=30, 35)	Proteus mirabilis - Favorable (n=11,5)	Enterobacter cloacae - Favorable (n= 7, 11)	Pseudomonas aeruginosa - Favorable (n=8, 13)
CAZ-AVI	129	23	11	5	6
Doripenem	127	18	1	8	8

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=292, 306)	Klebsiella pneumoniae - Favorable (n=44, 56)	Proteus mirabilis - Favorable (n=17, 13)	Enterobacter cloacae - Favorable (n= 11,13)	Pseudomonas aeruginosa - Favorable (n=18, 20)
CAZ-AVI	198	32	16	6	9
Doripenem	189	30	6	9	13

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=19, 18)	Klebsiella pneumoniae - Favorable (n=2, 1)	Proteus mirabilis - Favorable (n=1, 0)	Pseudomonas aeruginosa - Favorable (n=0, 1)
CAZ-AVI	19	2	1	0
Doripenem	17	1	0	1

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=32, 28)	Klebsiella pneumoniae - Favorable (n=4, 2)	Proteus mirabilis - Favorable (n=1, 0)	Pseudomonas aeruginosa - Favorable (n=1, 2)
CAZ-AVI	29	3	1	1
Doripenem	27	2	0	2

Intervention	Participant (Number)
	E. coli (MIC: <=0.008) - Favorable (n=4,4)	E. coli (MIC: 0.015) - Favorable (n=5, 6)	E. coli (MIC: 0.03) - Favorable (n=18, 21)	E. coli (MIC: 0.06) - Favorable (n=95, 111)	E. coli (MIC: 0.12) - Favorable (n=68, 54)	E. coli (MIC: 0.25) - Favorable (n=19, 18)	E. coli (MIC: 0.5) - Favorable (n=2, 5)	E. coli (MIC: 1) - Favorable (n=2, 0)	E. coli (MIC: 2) - Favorable (n=1, 0)	E. coli (MIC: 4) - Favorable (n=0, 0)	E. coli (MIC: 8) - Favorable (n=0, 0)	E. coli (MIC: 16) - Favorable (n=0, 0)	E. coli (MIC: 32) - Favorable (n=0, 0)	E. coli (MIC: >32) - Favorable (n=0, 0)	Kleb.pneumoniae (MIC: <=0.008)-Favorable(n=0, 0)	Kleb. pneumoniae (MIC: 0.015) - Favorable (n=1, 0)	Kleb. pneumoniae (MIC: 0.03) - Favorable (n=1, 2)	Kleb. pneumoniae (MIC: 0.06) - Favorable (n=5, 7)	Kleb.pneumoniae (MIC: 0.12) -Favorable(n=8, 9)	Kleb. pneumoniae (MIC: 0.25) - Favorable (n=3, 7)	Kleb. pneumoniae (MIC: 0.5) - Favorable (n=6, 11)	Kleb. pneumoniae (MIC: 1) - Favorable (n=6, 4)	Kleb. pneumoniae (MIC: 2) - Favorable (n= 2, 1)	Kleb. pneumoniae (MIC: 4) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: 8) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: 16) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: 32) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: >32) - Favorable (n=0, 1)	Proteus mirabilis (MIC:<=0.008)- Favorable (n=0,0)	Proteus mirabilis (MIC: 0.015)- Favorable (n=1,0)	Proteus mirabilis (MIC: 0.03)- Favorable (n=9, 2)	Proteus mirabilis (MIC: 0.06)- Favorable (n=4,5)	Proteus mirabilis (MIC: 0.12)- Favorable (n=0,0)	Proteus mirabilis (MIC: 0.25)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 0.5)- Favorable (n=0,0)	Proteus mirabilis (MIC: 1)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 2)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 4)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 8)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 16)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 32)- Favorable (n=0, 0)	Proteus mirabilis (MIC: >32)- Favorable (n=0, 0)	Entero. cloacae (MIC: <=0.008)- Favorable (n= 0,0)	Entero. cloacae (MIC: 0.015)- Favorable (n= 0,0)	Entero. cloacae (MIC: 0.03)- Favorable (n= 1,0)	Entero. cloacae (MIC: 0.06)- Favorable (n= 0, 1)	Entero. cloacae (MIC: 0.12)- Favorable (n= 1,2)	Entero. cloacae (MIC: 0.25)- Favorable (n= 0,3)	Entero. cloacae (MIC: 0.5)- Favorable (n= 1,1)	Entero. cloacae (MIC: 1)- Favorable (n= 1,4)	Entero. cloacae (MIC: 2)- Favorable (n= 1,0)	Entero. cloacae (MIC: 4)- Favorable (n= 2,0)	Entero. cloacae (MIC: 8)- Favorable (n= 0,0)	Entero. cloacae (MIC: 16)- Favorable (n= 0,0)	Entero. cloacae (MIC: 32)- Favorable (n= 0,0)	Entero. cloacae (MIC: >32)- Favorable (n= 0,0)	P.aeruginosa (MIC: <=0.008) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.015) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.03) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.06) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.12) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.25) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.5) - Favorable (n=0,0)	P.aeruginosa (MIC: 1) - Favorable (n=1,4)	P.aeruginosa (MIC: 2) - Favorable (n=4,5)	P.aeruginosa (MIC: 4) - Favorable (n=5,6)	P.aeruginosa (MIC: 8) - Favorable (n=2,2)	P.aeruginosa (MIC: 16) - Favorable (n=0,1)	P.aeruginosa (MIC: 32) - Favorable (n=0,0)	P.aeruginosa (MIC: >32) - Favorable (n=1,0)
CAZ-AVI	2	5	17	83	56	13	2	1	1	0	0	0	0	0	0	1	1	4	7	1	4	6	2	0	0	0	0	0	0	1	9	4	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	1	4	1	1	0	0	1
Doripenem	4	5	17	94	40	8	2	0	0	0	0	0	0	0	0	0	2	7	6	2	8	3	0	0	0	0	0	1	0	0	0	4	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	1	4	0	0	0	0	0	0	0	0	0	0	0	0	0	2	5	4	1	1	0	0

Intervention	Participant (Number)
	E. coli (MIC: <=0.008) - Favorable (n=5, 6)	E. coli (MIC: 0.015) - Favorable (n=8, 7)	E. coli (MIC: 0.03) - Favorable (n=28, 35)	E. coli (MIC: 0.06) - Favorable (n=123, 139)	E. coli (MIC: 0.12) - Favorable (n=90, 81)	E. coli (MIC: 0.25) - Favorable (n=28, 25)	E. coli (MIC: 0.5) - Favorable (n=5, 6)	E. coli (MIC: 1) - Favorable (n=3, 0)	E. coli (MIC: 2) - Favorable (n=1, 0)	E. coli (MIC: 4) - Favorable (n=0, 0)	E. coli (MIC: 8) - Favorable (n=0, 0)	E. coli (MIC: 16) - Favorable (n=0, 0)	E. coli (MIC: 32) - Favorable (n=0, 0)	E. coli (MIC: >32) - Favorable (n=0, 0)	Kleb.pneumoniae (MIC: <=0.008)-Favorable(n=0, 0)	Kleb. pneumoniae (MIC: 0.015) - Favorable (n=1, 0)	Kleb. pneumoniae (MIC: 0.03) - Favorable (n=1, 2)	Kleb. pneumoniae (MIC: 0.06) - Favorable (n=9, 8)	Kleb.pneumoniae (MIC: 0.12) -Favorable(n=11, 10)	Kleb. pneumoniae (MIC: 0.25) - Favorable (n=4, 10)	Kleb. pneumoniae (MIC: 0.5) - Favorable (n=8, 16)	Kleb. pneumoniae (MIC: 1) - Favorable (n=8, 5)	Kleb. pneumoniae (MIC: 2) - Favorable (n= 2, 4)	Kleb. pneumoniae (MIC: 4) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: 8) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: 16) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: 32) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: >32) - Favorable (n=0, 1)	Proteus mirabilis (MIC:<=0.008)- Favorable (n=0,0)	Proteus mirabilis (MIC: 0.015)- Favorable (n=1,1)	Proteus mirabilis (MIC: 0.03)- Favorable (n=10, 5)	Proteus mirabilis (MIC: 0.06)- Favorable (n=6,6)	Proteus mirabilis (MIC: 0.12)- Favorable (n=0,0)	Proteus mirabilis (MIC: 0.25)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 0.5)- Favorable (n=0,1)	Proteus mirabilis (MIC: 1)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 2)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 4)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 8)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 16)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 32)- Favorable (n=0, 0)	Proteus mirabilis (MIC: >32)- Favorable (n=0, 0)	Entero. cloacae (MIC: <=0.008)- Favorable (n= 0,0)	Entero. cloacae (MIC: 0.015)- Favorable (n= 0,0)	Entero. cloacae (MIC: 0.03)- Favorable (n= 1,0)	Entero. cloacae (MIC: 0.06)- Favorable (n= 0, 1)	Entero. cloacae (MIC: 0.12)- Favorable (n= 3,2)	Entero. cloacae (MIC: 0.25)- Favorable (n= 1,4)	Entero. cloacae (MIC: 0.5)- Favorable (n= 1,1)	Entero. cloacae (MIC: 1)- Favorable (n= 2,5)	Entero. cloacae (MIC: 2)- Favorable (n= 1,0)	Entero. cloacae (MIC: 4)- Favorable (n= 2,0)	Entero. cloacae (MIC: 8)- Favorable (n= 0,0)	Entero. cloacae (MIC: 16)- Favorable (n= 0,0)	Entero. cloacae (MIC: 32)- Favorable (n= 0,0)	Entero. cloacae (MIC: >32)- Favorable (n= 0,0)	P.aeruginosa (MIC: <=0.008) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.015) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.03) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.06) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.12) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.25) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.5) - Favorable (n=0,2)	P.aeruginosa (MIC: 1) - Favorable (n=1,4)	P.aeruginosa (MIC: 2) - Favorable (n=5,5)	P.aeruginosa (MIC: 4) - Favorable (n=7,6)	P.aeruginosa (MIC: 8) - Favorable (n=2,2)	P.aeruginosa (MIC: 16) - Favorable (n=1,1)	P.aeruginosa (MIC: 32) - Favorable (n=0,0)	P.aeruginosa (MIC: >32) - Favorable (n=2,0)
CAZ-AVI	3	8	24	103	67	18	4	1	1	0	0	0	0	0	0	1	1	7	9	1	6	6	2	0	0	0	0	0	0	1	10	5	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	1	5	3	1	0	0	2
Doripenem	5	6	23	111	54	13	2	0	0	0	0	0	0	0	0	0	2	8	7	3	11	3	0	0	0	0	0	1	0	0	3	5	0	0	1	0	0	0	0	0	0	0	0	0	0	1	2	1	1	4	0	0	0	0	0	0	0	0	0	0	0	0	2	2	5	4	1	1	0	0

Intervention	Participant (Number)
	E. coli (MIC: <=0.008) - Favorable (n=1,1)	E. coli (MIC: 0.015) - Favorable (n=122, 119)	E. coli (MIC: 0.03) - Favorable (n=79, 89)	E. coli (MIC: 0.06) - Favorable (n=10, 8)	E. coli (MIC: 0.12) - Favorable (n=1, 2)	E. coli (MIC: 0.25) - Favorable (n=1, 0)	E. coli (MIC: 0.5) - Favorable (n=0, 0)	E. coli (MIC: 1) - Favorable (n=0, 0)	E. coli (MIC: 2) - Favorable (n=0, 0)	E. coli (MIC: 4) - Favorable (n=0, 0)	E. coli (MIC: 8) - Favorable (n=0, 0)	E. coli (MIC: 16) - Favorable (n=0, 0)	E. coli (MIC: >16) - Favorable (n=0, 0)	Kleb.pneumoniae (MIC: <=0.008)-Favorable(n=0, 0)	Kleb. pneumoniae (MIC: 0.015) - Favorable (n=1, 2)	Kleb. pneumoniae (MIC:0.03) - Favorable (n=15, 23)	Kleb. pneumoniae (MIC: 0.06) - Favorable (n=8, 12)	Kleb.pneumoniae (MIC: 0.12) -Favorable(n=3, 2)	Kleb. pneumoniae (MIC: 0.25) - Favorable (n=2, 2)	Kleb. pneumoniae (MIC: 0.5) - Favorable (n=1, 0)	Kleb. pneumoniae (MIC: 1) - Favorable (n=1, 0)	Kleb. pneumoniae (MIC: 2) - Favorable (n= 0,0)	Kleb. pneumoniae (MIC: 4) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: 8) - Favorable (n=0, 1)	Kleb. pneumoniae (MIC: 16) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: >16) - Favorable (n=1, 0)	Proteus mirabilis (MIC:<=0.008)- Favorable (n=0,0)	Proteus mirabilis (MIC: 0.015)- Favorable (n=0,0)	Proteus mirabilis (MIC: 0.03)- Favorable (n=1,0)	Proteus mirabilis (MIC: 0.06)- Favorable (n=2,2)	Proteus mirabilis (MIC: 0.12)- Favorable (n=4,2)	Proteus mirabilis (MIC: 0.25)- Favorable (n=6, 3)	Proteus mirabilis (MIC: 0.5)- Favorable (n=1,0)	Proteus mirabilis (MIC: 1)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 2)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 4)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 8)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 16)- Favorable (n=0, 0)	Proteus mirabilis (MIC: >16)- Favorable (n=0, 0)	Entero. cloacae (MIC: <=0.008)- Favorable (n= 0,0)	Entero. cloacae (MIC: 0.015)- Favorable (n= 1,1)	Entero. cloacae (MIC: 0.03)- Favorable (n= 1,4)	Entero. cloacae (MIC: 0.06)- Favorable (n= 2, 1)	Entero. cloacae (MIC: 0.12)- Favorable (n= 0,4)	Entero. cloacae (MIC: 0.25)- Favorable (n= 0,0)	Entero. cloacae (MIC: 0.5)- Favorable (n= 3,0)	Entero. cloacae (MIC: 1)- Favorable (n= 0,1)	Entero. cloacae (MIC: 2)- Favorable (n= 0,0)	Entero. cloacae (MIC: 4)- Favorable (n= 0,0)	Entero. cloacae (MIC: 8)- Favorable (n= 0,0)	Entero. cloacae (MIC: 16)- Favorable (n= 0,0)	Entero. cloacae (MIC: >16)- Favorable (n= 0,0)	P.aeruginosa (MIC: <=0.008) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.015) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.03) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.06) - Favorable (n=2,3)	P.aeruginosa (MIC: 0.12) - Favorable (n=1,2)	P.aeruginosa (MIC: 0.25) - Favorable (n=2,4)	P.aeruginosa (MIC: 0.5) - Favorable (n=2,1)	P.aeruginosa (MIC: 1) - Favorable (n=1,3)	P.aeruginosa (MIC: 2) - Favorable (n=1,0)	P.aeruginosa (MIC: 4) - Favorable (n=0,2)	P.aeruginosa (MIC: 8) - Favorable (n=1,1)	P.aeruginosa (MIC: 16) - Favorable (n=2,1)	P.aeruginosa (MIC: >16) - Favorable (n=1,1)
CAZ-AVI	1	106	64	7	1	1	0	0	0	0	0	0	0	0	1	12	7	2	1	1	1	0	0	0	0	1	0	0	1	2	4	6	1	0	0	0	0	0	0	0	1	1	1	0	0	2	0	0	0	0	0	0	0	0	0	2	0	2	2	0	1	0	0	0	1
Doripenem	1	95	70	3	1	0	0	0	0	0	0	0	0	0	1	18	6	2	1	0	0	0	0	1	0	0	0	0	0	1	2	1	0	0	0	0	0	0	0	0	1	1	1	4	0	0	1	0	0	0	0	0	0	0	0	3	2	1	1	2	0	1	1	1	1

Intervention	Participant (Number)
	E. coli (MIC: <=0.008) - Favorable (n=1, 3)	E. coli (MIC: 0.015) - Favorable (n=160, 160)	E. coli (MIC: 0.03) - Favorable (n=112, 123)	E. coli (MIC: 0.06) - Favorable (n=14, 10)	E. coli (MIC: 0.12) - Favorable (n=3, 3)	E. coli (MIC: 0.25) - Favorable (n=1, 0)	E. coli (MIC: 0.5) - Favorable (n=0,0)	E. coli (MIC: 1) - Favorable (n=0, 0)	E. coli (MIC: 2) - Favorable (n=0, 0)	E. coli (MIC: 4) - Favorable (n=0, 0)	E. coli (MIC: 8) - Favorable (n=0, 0)	E. coli (MIC: 16) - Favorable (n=0, 0)	E. coli (MIC: >16) - Favorable (n=0, 0)	Kleb.pneumoniae (MIC: <=0.008)-Favorable(n=0, 0)	Kleb. pneumoniae (MIC: 0.015) - Favorable (n=1, 3)	Kleb. pneumoniae (MIC: 0.03)-Favorable (n=22, 27)	Kleb. pneumoniae (MIC: 0.06)- Favorable (n=11, 16)	Kleb.pneumoniae (MIC: 0.12) -Favorable(n=4,4)	Kleb. pneumoniae (MIC: 0.25) - Favorable (n=2,3)	Kleb. pneumoniae (MIC: 0.5) - Favorable (n=2, 1)	Kleb. pneumoniae (MIC: 1) - Favorable (n=1, 0)	Kleb. pneumoniae (MIC: 2) - Favorable (n= 0, 0)	Kleb. pneumoniae (MIC: 4) - Favorable (n=0, 0)	Kleb. pneumoniae (MIC: 8) - Favorable (n=0, 1)	Kleb. pneumoniae (MIC: 16) - Favorable (n=0, 1)	Kleb. pneumoniae (MIC: >16) - Favorable (n=1, 0)	Proteus mirabilis (MIC:<=0.008)- Favorable (n=0,0)	Proteus mirabilis (MIC: 0.015)- Favorable (n=0,0)	Proteus mirabilis (MIC: 0.03)- Favorable (n=1, 0)	Proteus mirabilis (MIC: 0.06)- Favorable (n=2,2)	Proteus mirabilis (MIC: 0.12)- Favorable (n=6,5)	Proteus mirabilis (MIC: 0.25)- Favorable (n=6, 4)	Proteus mirabilis (MIC: 0.5)- Favorable (n=2,2)	Proteus mirabilis (MIC: 1)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 2)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 4)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 8)- Favorable (n=0, 0)	Proteus mirabilis (MIC: 16)- Favorable (n=0, 0)	Proteus mirabilis (MIC: >16)- Favorable (n=0, 0)	Entero. cloacae (MIC: <=0.008)- Favorable (n= 0,0)	Entero. cloacae (MIC: 0.015)- Favorable (n= 3,1)	Entero. cloacae (MIC: 0.03)- Favorable (n= 1,5)	Entero. cloacae (MIC: 0.06)- Favorable (n= 3, 1)	Entero. cloacae (MIC: 0.12)- Favorable (n= 0, 4)	Entero. cloacae (MIC: 0.25)- Favorable (n= 0,1)	Entero. cloacae (MIC: 0.5)- Favorable (n= 4,0)	Entero. cloacae (MIC: 1)- Favorable (n= 0,1)	Entero. cloacae (MIC: 2)- Favorable (n= 0,0)	Entero. cloacae (MIC: 4)- Favorable (n= 0,0)	Entero. cloacae (MIC: 8)- Favorable (n= 0,0)	Entero. cloacae (MIC: 16)- Favorable (n= 0,0)	Entero. cloacae (MIC: >16)- Favorable (n= 0,0)	P.aeruginosa (MIC: <=0.008) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.015) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.03) - Favorable (n=0,0)	P.aeruginosa (MIC: 0.06) - Favorable (n=2,3)	P.aeruginosa (MIC: 0.12) - Favorable (n=2,2)	P.aeruginosa (MIC: 0.25) - Favorable (n=2,5)	P.aeruginosa (MIC: 0.5) - Favorable (n=2,1)	P.aeruginosa (MIC: 1) - Favorable (n=1,4)	P.aeruginosa (MIC: 2) - Favorable (n=1,0)	P.aeruginosa (MIC: 4) - Favorable (n=2,2)	P.aeruginosa (MIC: 8) - Favorable (n=2,1)	P.aeruginosa (MIC: 16) - Favorable (n=2,1)	P.aeruginosa (MIC: >16) - Favorable (n=2,1)
CAZ-AVI	1	127	89	10	1	1	0	0	0	0	0	0	0	0	1	16	10	2	1	1	1	0	0	0	0	1	0	0	1	2	5	6	2	0	0	0	0	0	0	0	2	1	1	0	0	2	0	0	0	0	0	0	0	0	0	2	1	2	2	0	1	1	1	0	2
Doripenem	3	119	86	4	2	0	0	0	0	0	0	0	0	0	2	21	7	2	2	0	0	0	0	1	0	0	0	0	0	1	4	2	2	0	0	0	0	0	0	0	1	2	1	4	0	0	1	0	0	0	0	0	0	0	0	3	2	2	1	3	0	1	1	1	1

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=214, 226)	Klebsiella pneumoniae - Favorable (n=32, 42)	Proteus mirabilis - Favorable (n=14, 7)	Enterobacter cloacae - Favorable (n= 7, 11)	Pseudomonas aeruginosa - Favorable (n=13, 18)
CAZ-AVI	180	26	14	5	8
Doripenem	176	29	4	8	13

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=214, 221)	Klebsiella pneumoniae - Favorable (n=31, 41)	Proteus mirabilis - Favorable (n=14, 7)	Enterobacter cloacae - Favorable (n= 7, 11)	Pseudomonas aeruginosa - Favorable (n=9, 13)
CAZ-AVI	180	25	14	5	7
Doripenem	171	28	4	8	9

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=22, 20)	Klebsiella pneumoniae - Favorable (n=2, 2)	Proteus mirabilis - Favorable (n=1, 0)	Pseudomonas aeruginosa - Favorable (n=0, 1)
CAZ-AVI	22	2	1	0
Doripenem	20	2	0	1

Intervention	Participants (Number)
	Favorable	Unfavorable	Indeterminate
CAZ-AVI	374	1	18
Doripenem	395	3	19

Intervention	Participants (Number)
	Number of patients with fever (>38°C) at baseline	Number afebrile at the time of the last obs	Number censored at the time of the last obs
CAZ-AVI	123	122	1
Doripenem	118	113	5

Intervention	Participants (Number)
	Clinical cure	Clinical failure	Indeterminate
CAZ-AVI	327	4	5
Doripenem	368	2	1

Intervention	Participants (Number)
	All patients - Clinical cure (n=51, 63)	Escherichia coli patients - Clin cure (n=23, 27)	Klebsiella pneumoniae patients-Clin cure(n=15, 23)	Pseudomonas aeruginosa patients-Clin cure(n=3,6)	Enterobacter cloacae patients-Clin cure(n=5,5)	Proteus mirabilis patients - Clin cure (n=0, 2)
CAZ-AVI	50	22	15	3	5	0
Doripenem	61	25	23	6	5	2

Intervention	Participants (Number)
	All patients - Clinical cure (n=48, 57)	Escherichia coli patients-Clin cure (n=23,27)	Klebsiella pneumoniae patients-Clin cure(n=14, 22)	Pseudomonas aeruginosa patients-Clin cure(n=1, 2)	Enterobacter cloacae patients-Clin cure(n=5,5)	Proteus mirabilis patients - Clin cure (n=0, 2)
CAZ-AVI	47	22	14	1	5	0
Doripenem	55	25	22	2	5	2

Intervention	Participants (Number)
	All patients - Clinical cure (n=75, 84)	Escherichia coli patients - Clin cure (n=36, 37)	Klebsiella pneumoniae patients-Clin cure(n=18,30)	Pseudomonas aeruginosa patients- Clin cure(n=7,6)	Enterobacter cloacae patients-Clin cure(n=7,6)	Proteus mirabilis patients - Clin cure (n=2, 5)
CAZ-AVI	67	33	17	5	5	2
Doripenem	75	31	28	6	5	5

Intervention	Participants (Number)
	Symptomatic resolution	Symptom persistence	Indeterminate
CAZ-AVI	276	103	14
Doripenem	276	124	17

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=250, 274)	Klebsiella pneumoniae - Favorable (n=34, 49)	Proteus mirabilis - Favorable (n=13, 11)	Enterobacter cloacae - Favorable (n= 9, 12)	Pseudomonas aeruginosa - Favorable (n=18, 18)
CAZ-AVI	250	34	13	9	17
Doripenem	274	48	11	12	17

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=249, 270)	Klebsiella pneumoniae - Favorable (n=33, 48)	Proteus mirabilis - Favorable (n=13,11)	Enterobacter cloacae - Favorable (n= 9, 12)	Pseudomonas aeruginosa - Favorable (n=10, 15)
CAZ-AVI	249	33	13	9	9
Doripenem	270	47	11	12	14

avibactam

Description

Cross-References

Synonyms (47)

Research Excerpts

Overview

Effects

Actions

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (3)

Drug Classes (4)

Protein Targets (6)

Inhibition Measurements

Other Measurements

Bioassays (146)

Research

Studies (357)

Market Indicators

Research Demand Index: 85.36

Study Types

Clinical Trials (42)

Trial Overview

Trial Outcomes

Microbiological Outcome for the Urine Pathogen P. Aeruginosa in ME Patients at the End of IV Therapy Visit

Number of Participants With Microbiological Outcome at the Test of Cure (TOC) Visit

Microbiological Outcome for the Urine Pathogen E. Coli in ME Patients at the End of IV Therapy Visit

Clinical Outcome in CE Patients at the Late Follow-up (LFU) Visit

Clinical Outcome in CE Patients at the TOC Visit

Clinical Outcome in Clinically Evaluable (CE) Patients at the End of Intravenous (IV) Therapy Visit

Microbiological Outcome for the Urine Pathogen C. Koseri in ME Patients at the End of IV Therapy Visit

Microbiological Outcome for the Urine Pathogen C. Koseri in ME Patients at the LFU Visit

Microbiological Outcome for the Urine Pathogen C. Koseri in ME Patients at the TOC Visit

Microbiological Outcome for the Urine Pathogen E. Cloacae in ME Patients at the End of IV Therapy Visit

Microbiological Outcome for the Urine Pathogen E. Cloacae in ME Patients at the TOC Visit

Microbiological Outcome for the Urine Pathogen E. Coli in ME Patients at the LFU Visit

Microbiological Outcome for the Urine Pathogen E. Coli in ME Patients at the TOC Visit

Microbiological Outcome for the Urine Pathogen P. Aeruginosa in ME Patients at the LFU Visit

Microbiological Outcome for the Urine Pathogen P. Aeruginosa in ME Patients at the TOC Visit

Microbiological Outcome for the Urine Pathogen P. Mirabilis in ME Patients at the End of IV Therapy Visit

Microbiological Outcome for the Urine Pathogen P. Mirabilis in ME Patients at the LFU Visit

Microbiological Outcome for the Urine Pathogen P. Mirabilis in ME Patients at the TOC Visit

Microbiological Outcome in ME Patients at the End of IV Therapy Visit

Microbiological Outcome in ME Patients at the LFU Visit

Number of Participants With Clinical Response at the End of Intravenous (IV) Therapy

Number of Participants With Clinical Response at the Late Follow-up Visit

Number of Participants With Clinical Response at the Test of Cure (TOC) Visit

Number of Participants With Clinical Response in CE Participants at the End of IV Therapy

Number of Participants With Clinical Response in CE Participants at the Late Follow-up Visit

Number of Participants With Clinical Response in Clinically Evaluable (CE) Participants at the Test of Cure Visit

Number of Participants With Microbiological Response at the End of IV Therapy

Number of Participants With Microbiological Response at the Test of Cure Visit

Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

Number of Participants With Microbiological Response at the Late Follow-up Visit

Per-pathogen Microbiological Response at LFU for Baseline Pathogen (ME at LFU Analysis Set)

Per-pathogen Microbiological Response at LFU for Baseline Pathogen (mMITT Analysis Set)

Per-pathogen Microbiological Response at LFU for Blood Only (Extended ME at LFU Analysis Set)

Per-pathogen Microbiological Response at LFU for Blood Only (ME at LFU Analysis Set)

Per-pathogen Microbiological Response at LFU for Blood Only (mMITT Analysis Set)

Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (Extended ME at TOC Analysis Set)

Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (ME at TOC Analysis Set)

Per-pathogen Microbiological Response at TOC by CAZ AVI MIC for Baseline Pathogen (mMITT Analysis Set)

Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (Extended ME at TOC Analysis Set)

Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (ME at TOC Analysis Set)

Per-pathogen Microbiological Response at TOC by Doripenem MIC for Baseline Pathogen (mMITT Analysis Set)

Per-pathogen Microbiological Response at TOC for Baseline Pathogen (Extended ME at TOC Analysis Set)

Per-pathogen Microbiological Response at TOC for Baseline Pathogen (ME at TOC Analysis Set)

Per-pathogen Microbiological Response at TOC for Baseline Pathogen (mMITT Analysis Set)

Per-pathogen Microbiological Response at TOC for Blood Only (Extended ME at TOC Analysis Set)

Per-pathogen Microbiological Response at TOC for Blood Only (ME at TOC Analysis Set)

Investigator Determined Clinical Response at LFU (CE at LFU Analysis Set)

Per-patient Microbiological Response at EOT (IV) (Extended ME at EOT (IV) Analysis Set)

Per-patient Microbiological Response at EOT (IV) (ME at EOT (IV) Analysis Set)

Per-patient Microbiological Response at EOT (IV) (mMITT Analysis Set)

Per-patient Microbiological Response at LFU (Extended ME at LFU Analysis Set)

Per-patient Microbiological Response at LFU (ME at LFU Analysis Set)

Per-patient Microbiological Response at LFU (mMITT Analysis Set)

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=26, 24)	Klebsiella pneumoniae - Favorable (n=2, 1)	Proteus mirabilis - Favorable (n=1, 0)	Pseudomonas aeruginosa - Favorable (n=1, 2)
CAZ-AVI	26	1	1	1
Doripenem	24	1	0	2

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=179, 198)	Klebsiella pneumoniae - Favorable (n=31, 36)	Proteus mirabilis - Favorable (n=11,5)	Enterobacter cloacae - Favorable (n= 7, 11)	Pseudomonas aeruginosa - Favorable (n=12, 16)
CAZ-AVI	129	24	11	5	7
Doripenem	131	19	1	8	9

Intervention	Participant (Number)
	Favorable	Unfavorable
cIAI:Best Available Therapy	5	0
cIAI:CAZ-AVI + Metronidazole	9	0
cUTI:Best Available Therapy	127	0
cUTI:CAZ-AVI	133	1

Intervention	Participant (Number)
	E. coli - Clinical cure (n=6, 4, 57, 59)	K. pneumoniae - Clinical cure (n=3, 5, 65, 55)	P. aeruginosa - clinical cure (n=1, 1, 5, 14)
cIAI:Best Available Therapy	2	2	1
cIAI:CAZ-AVI + Metronidazole	3	3	1
cUTI:Best Available Therapy	54	61	5
cUTI:CAZ-AVI	53	54	12

Intervention	Participant (Number)
	At least 1 failed - Clin. cure (n=4,7,12,7)	Antibiotics - Clin. cure (n=0,1,0,0)	Carbapenems - Clin. cure (n=1,0,1,2)	Comb of Sulf/Trime inc Deriv-Clin. cure(n=0,0,2,0)	Combs Of Peni. Inc B-Lact. Inhib.-Cure(n=1,3,0,2)	Cortico,Po. Comb W/Antibio.-Clin. cure(n=0,0,1,0)	First-Gen. Cephalosporins-Clin. cure (n=0,0,2,0)	Fluoroquinolones - Clin. cure (n=1,2,7,1)	Glycopeptide Antibacterials-Clin. cure (n=1,0,0,0)	Imidazole Derivatives - Clin. cure (n=2,3,0,0)	Other Aminoglycosides-Clin. cure (n=0,0,1,1)	Other Antibacterials-Clin. cure (n=0,1,1,0)	Other Antibio. F. Topic. Use-Clin. cure(n=0,0,1,0)	Penici. With Ext. Spectrum-Clin. cure(n=0,1,0,0)	Third-Gen.Cephalosporins -Clin. cure(n=2,4,3,2)
cIAI:Best Available Therapy	3	0	0	0	1	0	0	0	0	1	0	0	0	0	2
cIAI:CAZ-AVI + Metronidazole	7	1	0	0	3	0	0	2	0	3	0	1	0	1	4
cUTI:Best Available Therapy	12	0	1	2	0	1	2	7	0	0	1	1	1	0	3
cUTI:CAZ-AVI	6	0	1	0	2	0	0	1	0	0	1	0	0	0	2

Intervention	NG/ML (Geometric Mean)
CAZ (1)	23880.3
AVI (1)	3061.3
CAZ (2)	39465.3
AVI (2)	6304.1
CAZ (3)	14904.8
AVI (3)	1769.3

Intervention	Participant (Number)
	All cause mortality	Deaths due to disease progression	Number of patients with any AE withoutcome=death
cIAI:Best Available Therapy	0	0	0
cIAI:CAZ-AVI + Metronidazole	0	0	0
cUTI:Best Available Therapy	1	0	1
cUTI:CAZ-AVI	1	0	1

Intervention	Participant (Number)
	Treatment Change	Treatment Change - Crcl change	Treatment Change - Other	Treatment discontinuation	Treatment discontinuation - AE	Treatment discontinuation - Other	Treatment interrupted	Treatment interrupted - Change of infusion site
cIAI:Best Available Therapy	1	1	0	4	1	3	0	0
cIAI:CAZ-AVI + Metronidazole	0	0	0	0	0	0	0	0
cUTI:Best Available Therapy	8	5	3	3	1	2	0	0
cUTI:CAZ-AVI	11	10	1	1	1	0	1	1

Intervention	Participant (Number)
	Antibiotics - Clin. cure (n=0,1,0,0)	Carbapenems - Clin. cure (n=0,0,1,1)	Comb of Sulf/Trime inc Deriv-Clin. cure(n=0,0,2,0)	Combs Of Peni. Inc B-Lact. Inhib.-Cure(n=1,3,0,2)	Cortico,Po. Comb W/Antibio.-Clin. cure(n=0,0,1,0)	First-Gen. Cephalosporins-Clin. cure (n=0,0,2,0)	Fluoroquinolones - Clin. cure (n=0,2,5,1)	Imidazole Derivatives - Clin. cure (n=1,3,0,0)	Other Aminoglycosides-Clin. cure (n=0,0,0,1)	Other Antibacterials-Clin. cure (n=0,1,1,0)	Other Antibio. F. Topic. Use-Clin. cure(n=0,0,1,0)	Penici. With Ext. Spectrum-Clin. cure(n=0,1,0,0)	Third-Gen.Cephalosporins -Clin. cure(n=2,4,2,2)
cIAI:Best Available Therapy	0	0	0	1	0	0	0	1	0	0	0	0	2
cIAI:CAZ-AVI + Metronidazole	1	0	0	3	0	0	2	3	0	1	0	1	4
cUTI:Best Available Therapy	0	1	2	0	1	2	5	0	0	1	1	0	2
cUTI:CAZ-AVI	0	1	0	2	0	0	1	0	1	0	0	0	2

Intervention	Participant (Number)
	Escherichia coli - Favorable (n=6, 4, 57, 59)	Escherichia coli - Unfavorable (n=6, 4, 57, 59)	Escherichia coli - Indeterminate (n=6, 4, 57, 59)	Kleb. pneumoniae - Favorable (n=3, 5, 65, 55)	Kleb. pneumoniae - Unfavorable (n=3, 5, 65, 55)	Kleb. pneumoniae - Indeterminate (n=3, 5, 65, 55)	Pseudo. aeruginosa - Favorable (n=1, 1, 5, 14)	Pseudo. aeruginosa - Unfavorable (n=1, 1, 5, 14)	Pseudo. aeruginosa - Indeterminate (n=1, 1, 5, 14)
cIAI:Best Available Therapy	2	0	4	2	0	1	1	0	0
cIAI:CAZ-AVI + Metronidazole	3	0	1	3	0	2	1	0	0
cUTI:Best Available Therapy	38	16	3	43	19	3	3	2	0
cUTI:CAZ-AVI	52	3	4	46	8	1	11	2	1